$teva 2017 Q4 10-K

Concept	2017 Q4	2017 Q3	2017 Q2
Revenue	$5.459B	$5.611B	$5.720B
YoY Change	-15.91%	0.86%	13.54%
Cost Of Revenue	$3.127B	$2.967B	$2.865B
YoY Change	-5.47%	7.42%	32.58%
Gross Profit	$2.444B	$2.599B	$2.802B
YoY Change	-27.91%	-7.21%	-2.61%
Gross Profit Margin	44.77%	46.32%	48.99%
Selling, General & Admin	$935.0M	$1.215B	$1.307B
YoY Change	-29.01%	-2.8%	3.48%
% of Gross Profit	38.26%	46.75%	46.65%
Research & Development	$346.0M	$531.0M	$469.0M
YoY Change	-46.77%	-19.91%	25.07%
% of Gross Profit	14.16%	20.43%	16.74%
Depreciation & Amortization	$528.0M	$527.0M	$577.0M
YoY Change	59.04%	-8.67%	86.13%
% of Gross Profit	21.6%	20.28%	20.59%
Operating Expenses	$1.364B	$1.746B	$1.776B
YoY Change	-24.85%	40.81%	4.72%
Operating Profit	$1.080B	$378.0M	-$5.740B
YoY Change	-31.43%	-75.78%	-586.03%
Interest Expense	-$286.0M	-$235.0M	-$300.0M
YoY Change	-63.19%	56.67%	185.71%
% of Operating Profit	-26.48%	-62.17%
Other Income/Expense, Net	$95.00M	-$259.0M	-$238.0M
YoY Change
Pretax Income	-$13.21B	$119.0M	-$5.978B
YoY Change	1345.08%	-80.65%	-2435.16%
Income Tax	-$410.0M	-$494.0M	-$22.00M
% Of Pretax Income		-415.13%
Net Earnings	-$11.54B	$595.0M	-$5.970B
YoY Change	1085.51%	44.42%	-2450.39%
Net Earnings / Revenue	-211.3%	10.6%	-104.37%
Basic Earnings Per Share	-$11.41	$0.52	-$5.94
Diluted Earnings Per Share	-$11.41	$0.52	-$5.94
COMMON SHARES
Basic Shares Outstanding		1.017B shares	1.017B shares
Diluted Shares Outstanding		1.017B shares	1.017B shares

Concept	2017 Q4	2017 Q3	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$963.0M	$680.0M	$599.0M
YoY Change	-2.53%	-56.33%	-91.42%
Cash & Equivalents	$963.0M	$680.0M	$599.0M
Short-Term Investments
Other Short-Term Assets	$701.0M	$3.062B	$1.544B
YoY Change	-81.37%	27.11%	-25.23%
Inventory	$4.924B	$5.060B	$5.132B
Prepaid Expenses	$1.100B
Receivables	$7.128B	$7.424B	$7.320B
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$15.38B	$16.23B	$14.60B
YoY Change	-10.72%	-6.67%	-20.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.673B	$8.001B	$8.043B
YoY Change	-4.95%	-4.51%	20.17%
Goodwill	$28.41B
YoY Change	-36.02%
Intangibles	$17.64B
YoY Change	-17.9%
Long-Term Investments
YoY Change
Other Assets	$932.0M	$1.585B	$2.018B
YoY Change	-24.53%	-49.34%	-23.53%
Total Long-Term Assets	$55.23B	$69.86B	$71.76B
YoY Change	-27.16%	-14.14%	81.32%
TOTAL ASSETS
Total Short-Term Assets	$15.38B	$16.23B	$14.60B
Total Long-Term Assets	$55.23B	$69.86B	$71.76B
Total Assets	$70.62B	$86.08B	$86.36B
YoY Change	-24.12%	-12.83%	49.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.069B	$2.370B	$2.278B
YoY Change	-4.08%	-52.15%	-40.91%
Accrued Expenses	$3.563B	$3.295B	$3.470B
YoY Change	-16.44%
Deferred Revenue
YoY Change
Short-Term Debt	$1.000M	$827.0M	$981.0M
YoY Change	-93.33%
Long-Term Debt Due	$2.880B	$1.904B	$265.0M
YoY Change	255.56%	-48.2%	-90.8%
Total Short-Term Liabilities	$17.92B	$16.94B	$15.46B
YoY Change	-3.07%	-12.15%	7.26%
LONG-TERM LIABILITIES
Long-Term Debt	$28.83B	$31.97B	$33.81B
YoY Change	-11.36%	-3.64%	320.68%
Other Long-Term Liabilities	$1.843B	$1.960B	$2.038B
YoY Change	12.45%	40.8%	50.63%
Total Long-Term Liabilities	$33.95B	$33.93B	$35.84B
YoY Change	-14.22%	-1.85%	281.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.92B	$16.94B	$15.46B
Total Long-Term Liabilities	$33.95B	$33.93B	$35.84B
Total Liabilities	$51.87B	$57.41B	$58.36B
YoY Change	-10.67%	-9.76%	110.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.803B
YoY Change	-127.95%
Common Stock	$54.00M
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$4.149B
YoY Change	-1.07%
Treasury Stock Shares	107.0M shares
Shareholders Equity	$17.36B	$28.67B	$27.99B
YoY Change
Total Liabilities & Shareholders Equity	$70.62B	$86.08B	$86.36B
YoY Change	-24.12%	-12.83%	49.09%

Concept	2017 Q4	2017 Q3	2017 Q2
OPERATING ACTIVITIES
Net Income	-$11.54B	$595.0M	-$5.970B
YoY Change	1085.51%	44.42%	-2450.39%
Depreciation, Depletion And Amortization	$528.0M	$527.0M	$577.0M
YoY Change	59.04%	-8.67%	86.13%
Cash From Operating Activities	$859.0M	$155.0M	$741.0M
YoY Change	854.44%	-89.39%	-23.05%
INVESTING ACTIVITIES
Capital Expenditures	-$267.0M	-$212.0M	-$193.0M
YoY Change	-19.82%	-4.07%	10.29%
Acquisitions
YoY Change
Other Investing Activities	$2.179B	$956.0M	-$199.0M
YoY Change	150.17%	-102.98%	298.0%
Cash From Investing Activities	$1.912B	$744.0M	-$392.0M
YoY Change	255.39%	-102.3%	74.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.506B	-825.0M	-651.0M
YoY Change	257.49%	-103.25%	-333.33%
NET CHANGE
Cash From Operating Activities	859.0M	155.0M	741.0M
Cash From Investing Activities	1.912B	744.0M	-392.0M
Cash From Financing Activities	-2.506B	-825.0M	-651.0M
Net Change In Cash	265.0M	74.00M	-302.0M
YoY Change	-463.01%	-101.35%	-129.7%
FREE CASH FLOW
Cash From Operating Activities	$859.0M	$155.0M	$741.0M
Capital Expenditures	-$267.0M	-$212.0M	-$193.0M
Free Cash Flow	$1.126B	$367.0M	$934.0M
YoY Change	166.19%	-78.18%	-17.93%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11560000000	USD
CY2016	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10044000000	USD
CY2015	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8296000000	USD
CY2017	us-gaap	Gross Profit GrossProfit	10825000000	USD
CY2016	us-gaap	Gross Profit GrossProfit	11859000000	USD
CY2015	us-gaap	Gross Profit GrossProfit	11356000000	USD
CY2017	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1848000000	USD
CY2016	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2111000000	USD
CY2015	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1525000000	USD
CY2017	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3656000000	USD
CY2016	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3860000000	USD
CY2015	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3478000000	USD
CY2017	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-184000000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-16265000000	USD
CY2016	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-18000000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	329000000	USD
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	9000000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	1588000000	USD
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-16.26
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.84
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-16.26
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.82
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	521000000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	634000000	USD
CY2016	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	8000000	USD
CY2015	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-121000000	USD
CY2017	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3000000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16525000000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	68000000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1573000000	USD
CY2015	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	140000000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	477000000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	-135000000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3000000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-319000000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	319000000	USD
CY2017	teva	Total Other Comprehensive Income Loss TotalOtherComprehensiveIncomeLoss	-1369000000	USD
CY2016	teva	Total Other Comprehensive Income Loss TotalOtherComprehensiveIncomeLoss	1264000000	USD
CY2015	teva	Total Other Comprehensive Income Loss TotalOtherComprehensiveIncomeLoss	613000000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15080000000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-953000000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	976000000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-875000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-445000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1102000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax	-10000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax	-23000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax	35000000	USD
CY2015	teva	Comprehensive Loss Attributable To Non Controlling Interests ComprehensiveLossAttributableToNonControllingInterests	8000000	USD
CY2016	teva	Comprehensive Loss Attributable To Non Controlling Interests ComprehensiveLossAttributableToNonControllingInterests	-78000000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-14959000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1516000000	USD
CY2017	teva	Comprehensive Loss Attributable To Non Controlling Interests ComprehensiveLossAttributableToNonControllingInterests	-121000000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	117000000	USD
CY2015Q4	teva	Other Equity OtherEquity	7000000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	35000000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	159000000	USD
CY2016	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	1303000000	USD
CY2016Q4	teva	Other Equity OtherEquity	-15000000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	133000000	USD
CY2017	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	901000000	USD
CY2017Q4	teva	Other Equity OtherEquity	-40000000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	388000000	USD
CY2016	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	1684000000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5391000000	USD
CY2016Q4	teva	Mandatoryconvertible Preferred Shares Issued During Period Shares New Issues MandatoryconvertiblePreferredSharesIssuedDuringPeriodSharesNewIssues	329000000	USD
CY2016	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	-261000000	USD
CY2015	teva	Disposition Of Non Controlling Interests DispositionOfNonControllingInterests	103000000	USD
CY2017	teva	Dividends To Preferred Shareholders DividendsToPreferredShareholders	-249000000	USD
CY2017	teva	Transactions With Non Controlling Interests TransactionsWithNonControllingInterests	-111000000	USD
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-43000000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	874000000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3477000000	USD
CY2017	teva	Payment To Aquire Marketable Securities And Other Assets PaymentToAquireMarketableSecuritiesAndOtherAssets	200000000	USD
CY2017	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	282000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2164000000	USD
CY2017	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	901000000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3300000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5750000000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	54000000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-25000000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	901000000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2002000000	USD
CY2016	teva	Payment To Aquire Marketable Securities And Other Assets PaymentToAquireMarketableSecuritiesAndOtherAssets	481000000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35740000000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25217000000	USD
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-660000000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5958000000	USD
CY2017	us-gaap	Asset Impairment Charges AssetImpairmentCharges	20882000000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	133000000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-13000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3507000000	USD
CY2016	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-1219000000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	124000000	USD
CY2016	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1645000000	USD
CY2016	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	14000000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5225000000	USD
CY2016	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	36148000000	USD
CY2016	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	212000000	USD
CY2017	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2017	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-74000000	USD
CY2017	teva	Deferred Income Taxes Net And Uncertain Tax Positions DeferredIncomeTaxesNetAndUncertainTaxPositions	-2331000000	USD
CY2016	teva	Deferred Income Taxes Net And Uncertain Tax Positions DeferredIncomeTaxesNetAndUncertainTaxPositions	15000000	USD
CY2016	teva	Gain From Revaluation Of Investments GainFromRevaluationOfInvestments	-140000000	USD
CY2017	teva	Profit From Sale Of Long Lived Assets And Investment ProfitFromSaleOfLongLivedAssetsAndInvestment	1090000000	USD
CY2016	teva	Profit From Sale Of Long Lived Assets And Investment ProfitFromSaleOfLongLivedAssetsAndInvestment	764000000	USD
CY2017	teva	Gain From Revaluation Of Investments GainFromRevaluationOfInvestments	0	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	175000000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	422000000	USD
CY2016	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	999000000	USD
CY2016	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	1998000000	USD
CY2016	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-169000000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	35000000	USD
CY2016	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	1303000000	USD
CY2017	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-1683000000	USD
CY2017	teva	Proceeds From Long Term Loans And Other Long Term Liabilities ProceedsFromLongTermLoansAndOtherLongTermLiabilities	506000000	USD
CY2016	teva	Proceeds From Long Term Loans And Other Long Term Liabilities ProceedsFromLongTermLoansAndOtherLongTermLiabilities	25252000000	USD
CY2017	teva	Payments Of Dividends Preferred Stock PaymentsOfDividendsPreferredStock	260000000	USD
CY2016	teva	Payments Of Dividends Preferred Stock PaymentsOfDividendsPreferredStock	255000000	USD
CY2017	teva	Venezuela Impairment Of Net Monetary Assets VenezuelaImpairmentOfNetMonetaryAssets	42000000	USD
CY2017	us-gaap	Interest Paid InterestPaid	795000000	USD
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	106000000	USD
CY2016	us-gaap	Interest Paid InterestPaid	290000000	USD
CY2015	us-gaap	Interest Paid InterestPaid	243000000	USD
CY2015	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	802000000	USD
CY2014Q4	teva	Shares Issued To Purchase Actavis Generics SharesIssuedToPurchaseActavisGenerics	0	USD
CY2016	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	341000000	USD
CY2014Q4	teva	Shares Transferred To Takeda SharesTransferredToTakeda	0	USD
CY2014Q4	teva	Actavis Contingent Consideration ActavisContingentConsideration	0	USD
CY2015Q4	teva	Actavis Contingent Consideration ActavisContingentConsideration	0	USD
CY2017	teva	Increase Decrease In Certain Current Assets Excluding Inventories IncreaseDecreaseInCertainCurrentAssetsExcludingInventories	514000000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	199000000	USD
CY2017	teva	Increase Decrease In Certain Current Liabilities Excluding Debt IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt	-1801000000	USD
CY2017	teva	Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation	-363000000	USD
CY2016	teva	Increase Decrease In Certain Current Assets Excluding Inventories IncreaseDecreaseInCertainCurrentAssetsExcludingInventories	343000000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	372000000	USD
CY2016	teva	Increase Decrease In Certain Current Liabilities Excluding Debt IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt	640000000	USD
CY2016	teva	Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation	1219000000	USD
CY2015	teva	Increase Decrease In Certain Current Assets Excluding Inventories IncreaseDecreaseInCertainCurrentAssetsExcludingInventories	763000000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	129000000	USD
CY2015	teva	Increase Decrease In Certain Current Liabilities Excluding Debt IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt	-12000000	USD
CY2015	teva	Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation	967000000	USD
CY2017	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	658000000	USD
CY2016	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-517000000	USD
CY2015	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	87000000	USD
CY2016	teva	Other Revenue OtherRevenue	343000000	USD
CY2015	teva	Other Revenue OtherRevenue	140000000	USD
CY2015	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	127000000	USD
CY2016	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	134000000	USD
CY2017	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	164000000	USD
CY2017	us-gaap	Advertising Expense AdvertisingExpense	318000000	USD
CY2016	us-gaap	Advertising Expense AdvertisingExpense	312000000	USD
CY2015	us-gaap	Advertising Expense AdvertisingExpense	297000000	USD
CY2017	teva	Percentage Of Consolidated Sales In North America PercentageOfConsolidatedSalesInNorthAmerica	53	pure
CY2017Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	254000000	USD
CY2016Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	1201000000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1774000000	USD
CY2016Q4	teva	Payments On Account PaymentsOnAccount	634000000	USD
CY2016Q4	us-gaap	Land Land	439000000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11926000000	USD
CY2016Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	27025000000	USD
CY2017Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	26172000000	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	103000000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	985000000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	986000000	USD
CY2017Q4	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	19000000	USD
CY2016	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	44000000	USD
CY2017Q4	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	20000000	USD
CY2016	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	43000000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	19000000	USD
CY2017Q4	teva	Total Maturities Of Debt Securities Including Treasury Bills TotalMaturitiesOfDebtSecuritiesIncludingTreasuryBills	37000000	USD
CY2017	us-gaap	Depreciation Depreciation	632000000	USD
CY2017	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	544000000	USD
CY2016	us-gaap	Depreciation Depreciation	501000000	USD
CY2015	us-gaap	Depreciation Depreciation	449000000	USD
CY2017	teva	Capitalized Land Lease Estimated Useful Lives Minimum CapitalizedLandLeaseEstimatedUsefulLivesMinimum	30	pure
CY2017	teva	Capitalized Land Lease Estimated Useful Lives Maximum CapitalizedLandLeaseEstimatedUsefulLivesMaximum	99	pure
CY2016Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	5748000000	USD
CY2016Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	3331000000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3853000000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4505000000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12178000000	USD
CY2017Q4	us-gaap	Land Land	390000000	USD
CY2017Q4	teva	Payments On Account PaymentsOnAccount	634000000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	2016000000	USD
CY2017Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	3329000000	USD
CY2017Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	5809000000	USD
CY2016	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-446000000	USD
CY2017	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	920000000	USD
CY2017	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	1157000000	USD
CY2017Q4	teva	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development Gross BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopmentGross	4343000000	USD
CY2016Q4	teva	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development Gross BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopmentGross	9183000000	USD
CY2017Q4	us-gaap	Finite Lived Trade Names Gross FiniteLivedTradeNamesGross	617000000	USD
CY2016Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	18180000000	USD
CY2017Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	21011000000	USD
CY2016Q4	us-gaap	Finite Lived Trade Names Gross FiniteLivedTradeNamesGross	625000000	USD
CY2016Q4	teva	Finite Lived Product Rights Accumulated Amortization FiniteLivedProductRightsAccumulatedAmortization	6460000000	USD
CY2017Q4	teva	Finite Lived Product Rights Accumulated Amortization FiniteLivedProductRightsAccumulatedAmortization	8276000000	USD
CY2017Q4	teva	Finite Lived Trade Names Accumulated Amortization FiniteLivedTradeNamesAccumulatedAmortization	55000000	USD
CY2016Q4	teva	Finite Lived Trade Names Accumulated Amortization FiniteLivedTradeNamesAccumulatedAmortization	41000000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6501000000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8331000000	USD
CY2017Q4	teva	Finite Lived Product Rights Net FiniteLivedProductRightsNet	12735000000	USD
CY2016Q4	teva	Finite Lived Product Rights Net FiniteLivedProductRightsNet	11720000000	USD
CY2017Q4	teva	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopmentNet	4343000000	USD
CY2016Q4	teva	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopmentNet	9183000000	USD
CY2016Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	27988000000	USD
CY2017Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	25971000000	USD
CY2017Q4	teva	Tradenamesnet Tradenamesnet	562000000	USD
CY2016Q4	teva	Tradenamesnet Tradenamesnet	584000000	USD
CY2017Q4	teva	Future Amortization Expenses Year One FutureAmortizationExpensesYearOne	1309000000	USD
CY2017Q4	teva	Future Amortization Expenses Year Three FutureAmortizationExpensesYearThree	1218000000	USD
CY2017Q4	teva	Future Amortization Expenses Year Four FutureAmortizationExpensesYearFour	1071000000	USD
CY2017Q4	teva	Future Amortization Expenses Year Five FutureAmortizationExpensesYearFive	1109000000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1444000000	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	993000000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	838000000	USD
CY2017Q4	teva	Futureamortizationexpensesyeartwo Futureamortizationexpensesyeartwo	1246000000	USD
CY2017Q4	teva	Rebates Rebates	3077000000	USD
CY2016Q4	teva	Rebates Rebates	3482000000	USD
CY2016Q4	teva	Chargebacks Chargebacks	1584000000	USD
CY2017Q4	teva	Chargebacks Chargebacks	1849000000	USD
CY2016Q4	teva	Other Other	200000000	USD
CY2017Q4	teva	Other Other	267000000	USD
CY2017Q4	teva	Medicaid Medicaid	1908000000	USD
CY2016Q4	us-gaap	Notes Payable NotesPayable	6158000000	USD
CY2016Q4	teva	Long Term Debentures LongTermDebentures	24000000	USD
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	-810000000	USD
CY2016Q4	teva	Longtermderivativeinstruments Longtermderivativeinstruments	2000000	USD
CY2016Q4	teva	Medicaid Medicaid	1729000000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	32524000000	USD
CY2017Q4	teva	Term Loan Jpy35 Libor Plus TermLoanJPY35LiborPlus	JPY LIBOR +0.3%
CY2017Q4	teva	Term Loan Usd2 Point5 Billion1 TermLoanUSD2Point5Billion1	LIBOR +1.1375%
CY2017Q4	teva	Term Loan Usd2 Point5 Billion2 TermLoanUSD2Point5Billion2	LIBOR +1.50%
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4010000000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4295000000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	4207000000	USD
CY2017	teva	Revenuerecognitiontextblock Revenuerecognitiontextblock	<div><table style='border-collapse:collapse;' ><tr style='height:15pt;' ><td colspan='6' rowspan='1' style='width:444.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:444.75pt;' ><font style='font-family:Times New Roman;font-size:11pt;font-weight:bold;color:#000000;' >NOTE 9—SALES RESERVES AND ALLOWANCES:</font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td></tr><tr style='height:4.5pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' ></font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td></tr><tr style='height:15pt;' ><td colspan='9' rowspan='1' style='width:525pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:525pt;' ><font style='font-family:Times New Roman;font-size:11pt;color:#000000;' > Sales reserves and allowances consisted of the following:</font></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='5' rowspan='1' style='width:147.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:147.75pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' >December 31,</font></td></tr><tr style='height:0.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:8.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td></tr><tr style='height:12.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='2' rowspan='1' style='width:67.5pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:67.5pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' >2017</font></td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td colspan='2' rowspan='1' style='width:69.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:69.75pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' >2016</font></td></tr><tr style='height:0.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:8.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='5' rowspan='1' style='width:147.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:147.75pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' >(U.S. $ in millions)</font></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >Rebates</font></td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >$</font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >3,077</font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >$</font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >3,482</font></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >Medicaid and other governmental allowances</font></td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >1,908</font></td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:7.5pt;font-weight:bold;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >1,729</font></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >Chargebacks</font></td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >1,849</font></td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:7.5pt;font-weight:bold;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >1,584</font></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >Returns</font></td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >780</font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >844</font></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >Other</font></td><td style='width:8.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:59.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >267</font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' ></font></td><td style='width:10.5pt;border-bottom-style:solid;border-bottom-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:59.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >200</font></td></tr><tr style='height:15.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > </font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:8.25pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >$</font></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >7,881</font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' ></font></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >$</font></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >7,839</font></td></tr><tr style='height:15.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:8.25pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:10.5pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td></tr></table></div>
CY2017	teva	Salesreservesandallowancescurrenttextblock Salesreservesandallowancescurrenttextblock	<div><table style='border-collapse:collapse;' ><tr style='height:15pt;' ><td colspan='6' rowspan='1' style='width:444.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:444.75pt;' ><font style='font-family:Times New Roman;font-size:11pt;font-weight:bold;color:#000000;' >NOTE 9—SALES RESERVES AND ALLOWANCES:</font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td></tr><tr style='height:4.5pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' ></font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td></tr><tr style='height:15pt;' ><td colspan='9' rowspan='1' style='width:525pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:525pt;' ><font style='font-family:Times New Roman;font-size:11pt;color:#000000;' > Sales reserves and allowances consisted of the following:</font></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='5' rowspan='1' style='width:147.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:147.75pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' >December 31,</font></td></tr><tr style='height:0.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:8.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td></tr><tr style='height:12.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='2' rowspan='1' style='width:67.5pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:67.5pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' >2017</font></td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td colspan='2' rowspan='1' style='width:69.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:69.75pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' >2016</font></td></tr><tr style='height:0.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:8.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' ></font></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='5' rowspan='1' style='width:147.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:147.75pt;' ><font style='font-family:Times New Roman;font-size:8pt;font-weight:bold;color:#000000;' >(U.S. $ in millions)</font></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >Rebates</font></td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >$</font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >3,077</font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >$</font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >3,482</font></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >Medicaid and other governmental allowances</font></td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >1,908</font></td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:7.5pt;font-weight:bold;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >1,729</font></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >Chargebacks</font></td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >1,849</font></td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:7.5pt;font-weight:bold;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >1,584</font></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >Returns</font></td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >780</font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >844</font></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >Other</font></td><td style='width:8.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:59.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >267</font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' ></font></td><td style='width:10.5pt;border-bottom-style:solid;border-bottom-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:59.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >200</font></td></tr><tr style='height:15.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > </font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:8.25pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >$</font></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >7,881</font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' ></font></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >$</font></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >7,839</font></td></tr><tr style='height:15.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ><font style='font-family:Arial;font-size:10pt;color:#000000;' ></font></td><td style='width:8.25pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:10.5pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td><td style='width:59.25pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ><font style='font-family:Calibri;font-size:11pt;color:#000000;' ></font></td></tr></table></div>
CY2016Q4	teva	Accrued Severance Pay Noncurrent AccruedSeverancePayNoncurrent	120000000	USD
CY2016Q4	teva	Employee Related Obligations Noncurrent EmployeeRelatedObligationsNoncurrent	317000000	USD
CY2017Q4	teva	Accrued Severance Pay Noncurrent AccruedSeverancePayNoncurrent	91000000	USD
CY2017Q4	teva	Employee Related Obligations Noncurrent EmployeeRelatedObligationsNoncurrent	273000000	USD
CY2017Q4	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	182000000	USD
CY2016Q4	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	197000000	USD
CY2017Q4	teva	Future Expected Domestic Minimum Benefit Payments Year One FutureExpectedDomesticMinimumBenefitPaymentsYearOne	7000000	USD
CY2017Q4	teva	Future Expected Domestic Minimum Benefit Payments Year Two FutureExpectedDomesticMinimumBenefitPaymentsYearTwo	7000000	USD
CY2017Q4	teva	Future Expected Domestic Minimum Benefit Payments Year Three FutureExpectedDomesticMinimumBenefitPaymentsYearThree	8000000	USD
CY2017Q4	teva	Future Expected Domestic Minimum Benefit Payments Year Four FutureExpectedDomesticMinimumBenefitPaymentsYearFour	9000000	USD
CY2017Q4	teva	Future Expected Domestic Minimum Benefit Payments Year Five FutureExpectedDomesticMinimumBenefitPaymentsYearFive	10000000	USD
CY2017Q4	teva	Future Expected Domestic Minimum Benefit Payments Years Six Through Ten FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen	53000000	USD
CY2016Q4	teva	Long Term Investments Earmarked For Domestic Severance Obligations LongTermInvestmentsEarmarkedForDomesticSeveranceObligations	152000000	USD
CY2017Q4	us-gaap	Defined Benefit Plans Estimated Future Employer Contributions In Next Fiscal Year DefinedBenefitPlansEstimatedFutureEmployerContributionsInNextFiscalYear	156000000	USD
CY2017Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2026-01-01
CY2017Q4	teva	Termloan Gbp TermloanGBP	0	USD
CY2017Q4	teva	Termloan Jpy1 TermloanJPY1	0	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2880000000	USD
CY2016Q4	teva	Termloan Gbp TermloanGBP	629000000	USD
CY2016Q4	teva	Termloan Jpy1 TermloanJPY1	68000000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	810000000	USD
CY2016Q4	us-gaap	Senior Notes SeniorNotes	27265000000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	1743000000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	14680000000	USD
CY2015Q4	teva	Line Of Credit Facility LineOfCreditFacility	3000000000	USD
CY2016Q4	teva	Line Of Credit Facility LineOfCreditFacility	4500000000	USD
CY2016Q4	teva	Fixed Rate Senior Notes FixedRateSeniorNotes	2.4	pure
CY2016Q4	teva	Term Loan Usd2 Point5 B TermLoanUSD2Point5B	2500000000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	160000000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	100000000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	73000000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	51000000	USD
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000000	USD
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	164000000	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	122000000	USD
CY2012	teva	Opana Net Sales OpanaNetSales	299000000	USD
CY2015Q4	teva	Modafinil Payment ModafinilPayment	1200000000	USD
CY2015Q4	teva	Andro Gel Annual Sales AndroGelAnnualSales	1050000000	USD
CY2016Q4	teva	Rugby Stettlement RugbyStettlement	225000000	USD
CY2010Q3	teva	Annual Sales Of Effexor AnnualSalesOfEffexor	2600000000	USD
CY2005Q1	teva	Annual Sales Of Lamictal AnnualSalesOfLamictal	950000000	USD
CY2008Q3	teva	Annual Sales Of Lamictal AnnualSalesOfLamictal	2300000000	USD
CY2005Q2	teva	Annual Sales Of Niaspan AnnualSalesOfNiaspan	416000000	USD
CY2013Q3	teva	Annual Sales Of Niaspan AnnualSalesOfNiaspan	1100000000	USD
CY2008Q3	teva	Annual Sales Of Aggrenox AnnualSalesOfAggrenox	340000000	USD
CY2017	teva	Annual Sales Of Aggrenox AnnualSalesOfAggrenox	455000000	USD
CY2010	teva	Annual Sales Of Actos AnnualSalesOfActos	3700000000	USD
CY2010	teva	Annual Sales Of Actoplus AnnualSalesOfActoplus	500000000	USD
CY2012Q3	teva	Annual Sales Of Actos AnnualSalesOfActos	2800000000	USD
CY2012Q3	teva	Annual Sales Of Actoplus AnnualSalesOfActoplus	430000000	USD
CY2015	teva	Nexium Settlement Payment NexiumSettlementPayment	24000000	USD
CY2017	teva	Annual Sales Of Namebda AnnualSalesOfNamebda	1400000000	USD
CY2009Q4	teva	Annual Sales Of Namebda AnnualSalesOfNamebda	1100000000	USD
CY2013Q4	teva	Compensatory Damages And Penalties CompensatoryDamagesAndPenalties	12400000	USD
CY2014Q1	teva	Punitive Damages PunitiveDamages	17900000	USD
CY2017	teva	Compensatory Damages For State Of Illonois CompensatoryDamagesForStateOfIllonois	100000000	USD
CY2015Q4	teva	Annual Sales Of Androgel At Time Of Sttlement AnnualSalesOfAndrogelAtTimeOfSttlement	350000000	USD
CY2015Q4	teva	Annual Sales Of Androgel AnnualSalesOfAndrogel	140000000	USD
CY2016Q4	teva	Ciprofloxacin Settlement CiprofloxacinSettlement	225000000	USD
CY2017Q4	teva	Annual Sales Of Lidoderm AnnualSalesOfLidoderm	1200000000	USD
CY2013Q4	teva	Annual Sales Of Lidoderm AnnualSalesOfLidoderm	1400000000	USD
CY2016Q4	teva	Annual Sales Of Intuniv AnnualSalesOfIntuniv	335000000	USD
CY2014Q4	teva	Annual Sales Of Intuniv AnnualSalesOfIntuniv	327000000	USD
CY2016	teva	Fcpa Settlement FcpaSettlement	519000000	USD
CY2016	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	0	shares
CY2017	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	0	shares
CY2015	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	7700000	shares
CY2016	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax	0	USD
CY2016	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	-477000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments And Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax	-26000000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.7
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.4
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.9
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y0M0D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y0M0D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y0M0D
CY2017Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	43121000	shares
CY2017Q4	teva	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2010 ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010	7.3	pure
CY2017Q4	teva	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance2010 ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010	44.32
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7400000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax	-6000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	32000000	USD
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax	1075000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax	-378000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	1453000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-1283000000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7000000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax	40000000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-2384000000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	312000000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax	175000000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-2769000000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7000000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax	-302000000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-1316000000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4000000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax	-442000000	USD
CY2015	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax	-1131000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax	-24000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-1107000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-6000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments And Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax	-413000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	-737000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	324000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	5000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	319000000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax	137000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax	2000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax	135000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax	0	USD
CY2015	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	135000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments And Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax	33000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax	4000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	-37000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax	-2000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-35000000	USD
CY2015	teva	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax1 OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax1	-1101000000	USD
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax	-355000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax	-3000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-352000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	33000000	USD
CY2016	teva	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax1 OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax1	-385000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments And Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax	-456000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	-140000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-316000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	3000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-319000000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax	-491000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax	-14000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax	-477000000	USD
CY2017	teva	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax1 OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax1	1453000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments And Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax	64000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	66000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-2000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-5000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3000000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax	-167000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax	-27000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax	-140000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax	0	USD
CY2017	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	-140000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments And Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax	-3000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax	-5000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	8000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax	-2000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	10000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax	9000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	23000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Before Reclassifications Before Tax OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax	-1374000000	USD
CY2015	teva	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax Total ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTaxTotal	-763000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-611000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-1000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-612000000	USD
CY2014Q4	teva	Accumulated Other Comprehensive Income Loss Other Adjustments AccumulatedOtherComprehensiveIncomeLossOtherAdjustments	-93000000	USD
CY2015Q4	teva	Accumulated Other Comprehensive Income Loss Other Adjustments AccumulatedOtherComprehensiveIncomeLossOtherAdjustments	-58000000	USD
CY2016Q4	teva	Accumulated Other Comprehensive Income Loss Other Adjustments AccumulatedOtherComprehensiveIncomeLossOtherAdjustments	-81000000	USD
CY2017Q4	teva	Accumulated Other Comprehensive Income Loss Other Adjustments AccumulatedOtherComprehensiveIncomeLossOtherAdjustments	-91000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Before Reclassifications Before Tax OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax	-1328000000	USD
CY2016	teva	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax Total ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTaxTotal	-151000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-1177000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-27000000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1204000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Before Reclassifications Before Tax OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax	969000000	USD
CY2017	teva	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax Total ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTaxTotal	-334000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	1303000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	3000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1306000000	USD
CY2016Q4	teva	Closing Market Price Of Company Common Stock ClosingMarketPriceOfCompanyCommonStock	36.25
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5000000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	120000000	USD
CY2015	teva	Average Market Price Of Company Common Stock During Period AverageMarketPriceOfCompanyCommonStockDuringPeriod	61.66
CY2017	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.36
CY2016	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.36
CY2016	teva	Average Market Price Of Company Common Stock During Period AverageMarketPriceOfCompanyCommonStockDuringPeriod	50.96
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The vesting period of the outstanding options, RSUs and PSUs is generally 1 to 4 years from the date of grant. The rights of the ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of the other ordinary shares of the Company. The contractual term of these options is primarily for seven years in prior plans and ten years for options granted under the 2010 plan described above.
CY2016Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	329000000	USD
CY2017	us-gaap	Convertible Preferred Stock Terms Of Conversion ConvertiblePreferredStockTermsOfConversion	13.3 and 16.0000
CY2016Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	337500	shares
CY2016Q1	teva	Aggregate Proceeds From Issuance Of Preferred Stock And Preference Stock AggregateProceedsFromIssuanceOfPreferredStockAndPreferenceStock	3620000000	USD
CY2017	us-gaap	Preferred Stock Dividend Rate Per Dollar Amount PreferredStockDividendRatePerDollarAmount	1000
CY2014Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	3000000000	USD
CY2015Q4	us-gaap	Share Price SharePrice	62.5
CY2015Q4	teva	Equivalent Share Units Approval For Grant EquivalentShareUnitsApprovalForGrant	43700000	shares
CY2016Q4	teva	Accrued Dividednds Payable AccruedDividedndsPayable	11000000	USD
CY2016Q4	teva	Convertible Preferred Shares Rate ConvertiblePreferredSharesRate	7	pure
CY2015	teva	Adss Offering AdssOffering	54000000	shares
CY2016	teva	Shares Transferred To Allergan SharesTransferredToAllergan	100300000	shares
CY2016Q4	teva	Dividend Mandatory Convertible Preferred Shares DividendMandatoryConvertiblePreferredShares	71.56
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1451000000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1516000000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1932000000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-19830000000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-692000000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	420000000	USD
CY2017	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	96000000	USD
CY2017	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-2029000000	USD
CY2016	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	209000000	USD
CY2016	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	312000000	USD
CY2015	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	149000000	USD
CY2015	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	485000000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	373000000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2306000000	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	481000000	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	40000000	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	298000000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	336000000	USD
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.265	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.24	pure
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4411000000	USD
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	206000000	USD
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	623000000	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-337000000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-212000000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-253000000	USD
CY2015	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	447000000	USD
CY2016	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	546000000	USD
CY2017	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	3817000000	USD
CY2016	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-19000000	USD
CY2015	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-99000000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	312000000	USD
CY2016Q4	teva	Deferred Tax Assets Carryforward Losses And Deductions Noncurrent DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent	1922000000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	5569000000	USD
CY2016Q4	teva	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Noncurrent DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNoncurrent	108000000	USD
CY2016Q4	teva	Deferred Tax Assets Liabilities Other Net Noncurrent DeferredTaxAssetsLiabilitiesOtherNetNoncurrent	-163000000	USD
CY2016Q4	teva	Deferred Tax Assets Liabilities Gross Noncurrent DeferredTaxAssetsLiabilitiesGrossNoncurrent	3099000000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance Noncurrent DeferredTaxAssetsValuationAllowanceNoncurrent	1689000000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-4788000000	USD
CY2017Q4	teva	Inventory Related InventoryRelated	-40000000	USD
CY2017Q4	teva	Sales Reserves And Allowance SalesReservesAndAllowance	-201000000	USD
CY2017Q4	teva	Provision For Legal Settlements ProvisionForLegalSettlements	-171000000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	3132000000	USD
CY2017Q4	teva	Deferred Tax Assets Carryforward Losses And Deductions Noncurrent DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent	1485000000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	231000000	USD
CY2017Q4	teva	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Noncurrent DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNoncurrent	142000000	USD
CY2017Q4	teva	Deferred Tax Assets Liabilities Other Net Noncurrent DeferredTaxAssetsLiabilitiesOtherNetNoncurrent	-125000000	USD
CY2017Q4	teva	Deferred Tax Assets Liabilities Gross Noncurrent DeferredTaxAssetsLiabilitiesGrossNoncurrent	1199000000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance Noncurrent DeferredTaxAssetsValuationAllowanceNoncurrent	1504000000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-2703000000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-4788000000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	56000000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	26000000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	-56000000	USD
CY2017	teva	Unrecognized Tax Benefits Of Acquirees Added In Period UnrecognizedTaxBenefitsOfAcquireesAddedInPeriod	273000000	USD
CY2017	teva	Unrecognized Tax Benefits Increases Decreases Other UnrecognizedTaxBenefitsIncreasesDecreasesOther	1000000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	734000000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	648000000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	713000000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	23000000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	71000000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	-103000000	USD
CY2016	teva	Unrecognized Tax Benefits Of Acquirees Added In Period UnrecognizedTaxBenefitsOfAcquireesAddedInPeriod	101000000	USD
CY2016	teva	Unrecognized Tax Benefits Increases Decreases Other UnrecognizedTaxBenefitsIncreasesDecreasesOther	-6000000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	-6000000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	43000000	USD

CY2017

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

11560000000

USD

CY2016

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

10044000000

USD

CY2015

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

8296000000

USD

CY2017

us-gaap

Gross Profit

GrossProfit

10825000000

USD

CY2016

us-gaap

Gross Profit

GrossProfit

11859000000

USD

CY2015

us-gaap

Gross Profit

GrossProfit

11356000000

USD

CY2017

us-gaap

Research And Development Expense Excluding Acquired In Process Cost

ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost

1848000000

USD

CY2016

us-gaap

Research And Development Expense Excluding Acquired In Process Cost

ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost

2111000000

USD

CY2015

us-gaap

Research And Development Expense Excluding Acquired In Process Cost

ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost

1525000000

USD

CY2017

us-gaap

Selling And Marketing Expense

SellingAndMarketingExpense

3656000000

USD

CY2016

us-gaap

Selling And Marketing Expense

SellingAndMarketingExpense

3860000000

USD

CY2015

us-gaap

Selling And Marketing Expense

SellingAndMarketingExpense

3478000000

USD

CY2017

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

-184000000

USD

CY2017

us-gaap

Net Income Loss

NetIncomeLoss

-16265000000

USD

CY2016

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

-18000000

USD

CY2016

us-gaap

Net Income Loss

NetIncomeLoss

329000000

USD

CY2015

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

9000000

USD

CY2015

us-gaap

Net Income Loss

NetIncomeLoss

1588000000

USD

CY2017

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-16.26

CY2016

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

0.07

CY2015

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

1.84

CY2017

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-16.26

CY2016

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

0.07

CY2015

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

1.82

CY2016

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

521000000

USD

CY2015

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

634000000

USD

CY2016

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

8000000

USD

CY2015

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-121000000

USD

CY2017

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-3000000

USD

CY2017

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-16525000000

USD

CY2016

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

68000000

USD

CY2015

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

1573000000

USD

CY2015

us-gaap

Goodwill Impairment Loss

GoodwillImpairmentLoss

0

USD

CY2017

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

140000000

USD

CY2016

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

477000000

USD

CY2015

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

-135000000

USD

CY2017

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

3000000

USD

CY2016

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

-319000000

USD

CY2015

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

319000000

USD

CY2017

teva

Total Other Comprehensive Income Loss

TotalOtherComprehensiveIncomeLoss

-1369000000

USD

CY2016

teva

Total Other Comprehensive Income Loss

TotalOtherComprehensiveIncomeLoss

1264000000

USD

CY2015

teva

Total Other Comprehensive Income Loss

TotalOtherComprehensiveIncomeLoss

613000000

USD

CY2017

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-15080000000

USD

CY2016

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-953000000

USD

CY2015

us-gaap

Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest

ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest

976000000

USD

CY2016

us-gaap

Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest

ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest

-875000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-445000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-1102000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax

OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax

-10000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax

OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax

-23000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax

OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax

35000000

USD

CY2015

teva

Comprehensive Loss Attributable To Non Controlling Interests

ComprehensiveLossAttributableToNonControllingInterests

8000000

USD

CY2016

teva

Comprehensive Loss Attributable To Non Controlling Interests

ComprehensiveLossAttributableToNonControllingInterests

-78000000

USD

CY2017

us-gaap

Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest

ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest

-14959000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

1516000000

USD

CY2017

teva

Comprehensive Loss Attributable To Non Controlling Interests

ComprehensiveLossAttributableToNonControllingInterests

-121000000

USD

CY2015

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

117000000

USD

CY2015Q4

teva

Other Equity

OtherEquity

7000000

USD

CY2016

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

35000000

USD

CY2016

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

159000000

USD

CY2016

us-gaap

Dividends Common Stock Cash

DividendsCommonStockCash

1303000000

USD

CY2016Q4

teva

Other Equity

OtherEquity

-15000000

USD

CY2017

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

0

USD

CY2017

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

133000000

USD

CY2017

us-gaap

Dividends Common Stock Cash

DividendsCommonStockCash

901000000

USD

CY2017Q4

teva

Other Equity

OtherEquity

-40000000

USD

CY2015

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

388000000

USD

CY2016

us-gaap

Minority Interest Decrease From Redemptions

MinorityInterestDecreaseFromRedemptions

1684000000

USD

CY2016

us-gaap

Stock Issued During Period Value New Issues

StockIssuedDuringPeriodValueNewIssues

5391000000

USD

CY2016Q4

teva

Mandatoryconvertible Preferred Shares Issued During Period Shares New Issues

MandatoryconvertiblePreferredSharesIssuedDuringPeriodSharesNewIssues

329000000

USD

CY2016

us-gaap

Dividends Preferred Stock Cash

DividendsPreferredStockCash

-261000000

USD

CY2015

teva

Disposition Of Non Controlling Interests

DispositionOfNonControllingInterests

103000000

USD

CY2017

teva

Dividends To Preferred Shareholders

DividendsToPreferredShareholders

-249000000

USD

CY2017

teva

Transactions With Non Controlling Interests

TransactionsWithNonControllingInterests

-111000000

USD

CY2017

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

-43000000

USD

CY2017

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

874000000

USD

CY2017

us-gaap

Proceeds From Sale And Maturity Of Marketable Securities

ProceedsFromSaleAndMaturityOfMarketableSecurities

3477000000

USD

CY2017

teva

Payment To Aquire Marketable Securities And Other Assets

PaymentToAquireMarketableSecuritiesAndOtherAssets

200000000

USD

CY2017

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

282000000

USD

CY2017

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

2164000000

USD

CY2017

us-gaap

Payments Of Dividends Common Stock

PaymentsOfDividendsCommonStock

901000000

USD

CY2017

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

0

USD

CY2017

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

3300000000

USD

CY2017

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-5750000000

USD

CY2017

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

54000000

USD

CY2017

us-gaap

Cash And Cash Equivalents Period Increase Decrease

CashAndCashEquivalentsPeriodIncreaseDecrease

-25000000

USD

CY2016

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

901000000

USD

CY2016

us-gaap

Proceeds From Sale And Maturity Of Marketable Securities

ProceedsFromSaleAndMaturityOfMarketableSecurities

2002000000

USD

CY2016

teva

Payment To Aquire Marketable Securities And Other Assets

PaymentToAquireMarketableSecuritiesAndOtherAssets

481000000

USD

CY2016

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-35740000000

USD

CY2016

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

25217000000

USD

CY2016

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

-660000000

USD

CY2016

us-gaap

Cash And Cash Equivalents Period Increase Decrease

CashAndCashEquivalentsPeriodIncreaseDecrease

-5958000000

USD

CY2017

us-gaap

Asset Impairment Charges

AssetImpairmentCharges

20882000000

USD

CY2017

us-gaap

Share Based Compensation

ShareBasedCompensation

133000000

USD

CY2017

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-13000000

USD

CY2017

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

3507000000

USD

CY2016

us-gaap

Increase Decrease In Operating Capital

IncreaseDecreaseInOperatingCapital

-1219000000

USD

CY2016

us-gaap

Share Based Compensation

ShareBasedCompensation

124000000

USD

CY2016

us-gaap

Asset Impairment Charges

AssetImpairmentCharges

1645000000

USD

CY2016

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

14000000

USD

CY2016

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

5225000000

USD

CY2016

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

36148000000

USD

CY2016

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

212000000

USD

CY2017

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

0

USD

CY2017

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

-74000000

USD

CY2017

teva

Deferred Income Taxes Net And Uncertain Tax Positions

DeferredIncomeTaxesNetAndUncertainTaxPositions

-2331000000

USD

CY2016

teva

Deferred Income Taxes Net And Uncertain Tax Positions

DeferredIncomeTaxesNetAndUncertainTaxPositions

15000000

USD

CY2016

teva

Gain From Revaluation Of Investments

GainFromRevaluationOfInvestments

-140000000

USD

CY2017

teva

Profit From Sale Of Long Lived Assets And Investment

ProfitFromSaleOfLongLivedAssetsAndInvestment

1090000000

USD

CY2016

teva

Profit From Sale Of Long Lived Assets And Investment

ProfitFromSaleOfLongLivedAssetsAndInvestment

764000000

USD

CY2017

teva

Gain From Revaluation Of Investments

GainFromRevaluationOfInvestments

0

USD

CY2017

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

175000000

USD

CY2016

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

422000000

USD

CY2016

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

999000000

USD

CY2016

us-gaap

Proceeds From Repayments Of Short Term Debt

ProceedsFromRepaymentsOfShortTermDebt

1998000000

USD

CY2016

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

-169000000

USD

CY2016

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

35000000

USD

CY2016

us-gaap

Payments Of Dividends Common Stock

PaymentsOfDividendsCommonStock

1303000000

USD

CY2017

us-gaap

Proceeds From Repayments Of Short Term Debt

ProceedsFromRepaymentsOfShortTermDebt

-1683000000

USD

CY2017

teva

Proceeds From Long Term Loans And Other Long Term Liabilities

ProceedsFromLongTermLoansAndOtherLongTermLiabilities

506000000

USD

CY2016

teva

Proceeds From Long Term Loans And Other Long Term Liabilities

ProceedsFromLongTermLoansAndOtherLongTermLiabilities

25252000000

USD

CY2017

teva

Payments Of Dividends Preferred Stock

PaymentsOfDividendsPreferredStock

260000000

USD

CY2016

teva

Payments Of Dividends Preferred Stock

PaymentsOfDividendsPreferredStock

255000000

USD

CY2017

teva

Venezuela Impairment Of Net Monetary Assets

VenezuelaImpairmentOfNetMonetaryAssets

42000000

USD

CY2017

us-gaap

Interest Paid

InterestPaid

795000000

USD

CY2017

us-gaap

Income Taxes Paid Net

IncomeTaxesPaidNet

106000000

USD

CY2016

us-gaap

Interest Paid

InterestPaid

290000000

USD

CY2015

us-gaap

Interest Paid

InterestPaid

243000000

USD

CY2015

us-gaap

Income Taxes Paid Net

IncomeTaxesPaidNet

802000000

USD

CY2014Q4

teva

Shares Issued To Purchase Actavis Generics

SharesIssuedToPurchaseActavisGenerics

0

USD

CY2016

us-gaap

Income Taxes Paid Net

IncomeTaxesPaidNet

341000000

USD

CY2014Q4

teva

Shares Transferred To Takeda

SharesTransferredToTakeda

0

USD

CY2014Q4

teva

Actavis Contingent Consideration

ActavisContingentConsideration

0

USD

CY2015Q4

teva

Actavis Contingent Consideration

ActavisContingentConsideration

0

USD

CY2017

teva

Increase Decrease In Certain Current Assets Excluding Inventories

IncreaseDecreaseInCertainCurrentAssetsExcludingInventories

514000000

USD

CY2017

us-gaap

Increase Decrease In Inventories

IncreaseDecreaseInInventories

199000000

USD

CY2017

teva

Increase Decrease In Certain Current Liabilities Excluding Debt

IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt

-1801000000

USD

CY2017

teva

Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information

NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation

-363000000

USD

CY2016

teva

Increase Decrease In Certain Current Assets Excluding Inventories

IncreaseDecreaseInCertainCurrentAssetsExcludingInventories

343000000

USD

CY2016

us-gaap

Increase Decrease In Inventories

IncreaseDecreaseInInventories

372000000

USD

CY2016

teva

Increase Decrease In Certain Current Liabilities Excluding Debt

IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt

640000000

USD

CY2016

teva

Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information

NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation

1219000000

USD

CY2015

teva

Increase Decrease In Certain Current Assets Excluding Inventories

IncreaseDecreaseInCertainCurrentAssetsExcludingInventories

763000000

USD

CY2015

us-gaap

Increase Decrease In Inventories

IncreaseDecreaseInInventories

129000000

USD

CY2015

teva

Increase Decrease In Certain Current Liabilities Excluding Debt

IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt

-12000000

USD

CY2015

teva

Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information

NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation

967000000

USD

CY2017

us-gaap

Increase Decrease In Other Current Assets

IncreaseDecreaseInOtherCurrentAssets

658000000

USD

CY2016

us-gaap

Increase Decrease In Other Current Assets

IncreaseDecreaseInOtherCurrentAssets

-517000000

USD

CY2015

us-gaap

Increase Decrease In Other Current Assets

IncreaseDecreaseInOtherCurrentAssets

87000000

USD

CY2016

teva

Other Revenue

OtherRevenue

343000000

USD

CY2015

teva

Other Revenue

OtherRevenue

140000000

USD

CY2015

us-gaap

Shipping Handling And Transportation Costs

ShippingHandlingAndTransportationCosts

127000000

USD

CY2016

us-gaap

Shipping Handling And Transportation Costs

ShippingHandlingAndTransportationCosts

134000000

USD

CY2017

us-gaap

Shipping Handling And Transportation Costs

ShippingHandlingAndTransportationCosts

164000000

USD

CY2017

us-gaap

Advertising Expense

AdvertisingExpense

318000000

USD

CY2016

us-gaap

Advertising Expense

AdvertisingExpense

312000000

USD

CY2015

us-gaap

Advertising Expense

AdvertisingExpense

297000000

USD

CY2017

teva

Percentage Of Consolidated Sales In North America

PercentageOfConsolidatedSalesInNorthAmerica

53

pure

CY2017Q4

us-gaap

Fair Value Net Asset Liability

FairValueNetAssetLiability

254000000

USD

CY2016Q4

us-gaap

Fair Value Net Asset Liability

FairValueNetAssetLiability

1201000000

USD

CY2016Q4

us-gaap

Property Plant And Equipment Other

PropertyPlantAndEquipmentOther

1774000000

USD

CY2016Q4

teva

Payments On Account

PaymentsOnAccount

634000000

USD

CY2016Q4

us-gaap

Land

439000000

USD

CY2016Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

11926000000

USD

CY2016Q4

us-gaap

Debt Instrument Fair Value

DebtInstrumentFairValue

27025000000

USD

CY2017Q4

us-gaap

Debt Instrument Fair Value

DebtInstrumentFairValue

26172000000

USD

CY2017Q4

us-gaap

Available For Sale Securities Amortized Cost

AvailableForSaleSecuritiesAmortizedCost

103000000

USD

CY2016Q4

us-gaap

Available For Sale Securities Amortized Cost

AvailableForSaleSecuritiesAmortizedCost

985000000

USD

CY2016Q4

us-gaap

Available For Sale Securities

AvailableForSaleSecurities

986000000

USD

CY2017Q4

us-gaap

Available For Sale Securities Gross Unrealized Gains

AvailableForSaleSecuritiesGrossUnrealizedGains

19000000

USD

CY2016

us-gaap

Available For Sale Securities Gross Unrealized Gains

AvailableForSaleSecuritiesGrossUnrealizedGains

44000000

USD

CY2017Q4

us-gaap

Available For Sale Securities Gross Unrealized Loss

AvailableForSaleSecuritiesGrossUnrealizedLoss

20000000

USD

CY2016

us-gaap

Available For Sale Securities Gross Unrealized Loss

AvailableForSaleSecuritiesGrossUnrealizedLoss

43000000

USD

CY2017Q4

us-gaap

Available For Sale Securities Debt Maturities Within One Year Fair Value

AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

19000000

USD

CY2017Q4

teva

Total Maturities Of Debt Securities Including Treasury Bills

TotalMaturitiesOfDebtSecuritiesIncludingTreasuryBills

37000000

USD

CY2017

us-gaap

Depreciation

632000000

USD

CY2017

us-gaap

Tangible Asset Impairment Charges

TangibleAssetImpairmentCharges

544000000

USD

CY2016

us-gaap

Depreciation

501000000

USD

CY2015

us-gaap

Depreciation

449000000

USD

CY2017

teva

Capitalized Land Lease Estimated Useful Lives Minimum

CapitalizedLandLeaseEstimatedUsefulLivesMinimum

30

pure

CY2017

teva

Capitalized Land Lease Estimated Useful Lives Maximum

CapitalizedLandLeaseEstimatedUsefulLivesMaximum

99

pure

CY2016Q4

us-gaap

Machinery And Equipment Gross

MachineryAndEquipmentGross

5748000000

USD

CY2016Q4

us-gaap

Buildings And Improvements Gross

BuildingsAndImprovementsGross

3331000000

USD

CY2016Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

3853000000

USD

CY2017Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

4505000000

USD

CY2017Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

12178000000

USD

CY2017Q4

us-gaap

Land

390000000

USD

CY2017Q4

teva

Payments On Account

PaymentsOnAccount

634000000

USD

CY2017Q4

us-gaap

Property Plant And Equipment Other

PropertyPlantAndEquipmentOther

2016000000

USD

CY2017Q4

us-gaap

Buildings And Improvements Gross

BuildingsAndImprovementsGross

3329000000

USD

CY2017Q4

us-gaap

Machinery And Equipment Gross

MachineryAndEquipmentGross

5809000000

USD

CY2016

us-gaap

Goodwill Foreign Currency Translation Gain Loss

GoodwillForeignCurrencyTranslationGainLoss

-446000000

USD

CY2017

us-gaap

Goodwill Other Increase Decrease

GoodwillOtherIncreaseDecrease

920000000

USD

CY2017

us-gaap

Goodwill Foreign Currency Translation Gain Loss

GoodwillForeignCurrencyTranslationGainLoss

1157000000

USD

CY2017Q4

teva

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development Gross

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopmentGross

4343000000

USD

CY2016Q4

teva

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development Gross

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopmentGross

9183000000

USD

CY2017Q4

us-gaap

Finite Lived Trade Names Gross

FiniteLivedTradeNamesGross

617000000

USD

CY2016Q4

us-gaap

Finite Lived Patents Gross

FiniteLivedPatentsGross

18180000000

USD

CY2017Q4

us-gaap

Finite Lived Patents Gross

FiniteLivedPatentsGross

21011000000

USD

CY2016Q4

us-gaap

Finite Lived Trade Names Gross

FiniteLivedTradeNamesGross

625000000

USD

CY2016Q4

teva

Finite Lived Product Rights Accumulated Amortization

FiniteLivedProductRightsAccumulatedAmortization

6460000000

USD

CY2017Q4

teva

Finite Lived Product Rights Accumulated Amortization

FiniteLivedProductRightsAccumulatedAmortization

8276000000

USD

CY2017Q4

teva

Finite Lived Trade Names Accumulated Amortization

FiniteLivedTradeNamesAccumulatedAmortization

55000000

USD

CY2016Q4

teva

Finite Lived Trade Names Accumulated Amortization

FiniteLivedTradeNamesAccumulatedAmortization

41000000

USD

CY2016Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

6501000000

USD

CY2017Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

8331000000

USD

CY2017Q4

teva

Finite Lived Product Rights Net

FiniteLivedProductRightsNet

12735000000

USD

CY2016Q4

teva

Finite Lived Product Rights Net

FiniteLivedProductRightsNet

11720000000

USD

CY2017Q4

teva

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development Net

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopmentNet

4343000000

USD

CY2016Q4

teva

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development Net

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopmentNet

9183000000

USD

CY2016Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

27988000000

USD

CY2017Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

25971000000

USD

CY2017Q4

teva

Tradenamesnet

562000000

USD

CY2016Q4

teva

Tradenamesnet

584000000

USD

CY2017Q4

teva

Future Amortization Expenses Year One

FutureAmortizationExpensesYearOne

1309000000

USD

CY2017Q4

teva

Future Amortization Expenses Year Three

FutureAmortizationExpensesYearThree

1218000000

USD

CY2017Q4

teva

Future Amortization Expenses Year Four

FutureAmortizationExpensesYearFour

1071000000

USD

CY2017Q4

teva

Future Amortization Expenses Year Five

FutureAmortizationExpensesYearFive

1109000000

USD

CY2017

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

1444000000

USD

CY2016

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

993000000

USD

CY2015

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

838000000

USD

CY2017Q4

teva

Futureamortizationexpensesyeartwo

1246000000

USD

CY2017Q4

teva

Rebates

3077000000

USD

CY2016Q4

teva

Rebates

3482000000

USD

CY2016Q4

teva

Chargebacks

1584000000

USD

CY2017Q4

teva

Chargebacks

1849000000

USD

CY2016Q4

teva

Other

200000000

USD

CY2017Q4

teva

Other

267000000

USD

CY2017Q4

teva

Medicaid

1908000000

USD

CY2016Q4

us-gaap

Notes Payable

NotesPayable

6158000000

USD

CY2016Q4

teva

Long Term Debentures

LongTermDebentures

24000000

USD

CY2016Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Next Twelve Months

LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

-810000000

USD

CY2016Q4

teva

Longtermderivativeinstruments

2000000

USD

CY2016Q4

teva

Medicaid

1729000000

USD

CY2016Q4

us-gaap

Long Term Debt

LongTermDebt

32524000000

USD

CY2017Q4

teva

Term Loan Jpy35 Libor Plus

TermLoanJPY35LiborPlus

JPY LIBOR +0.3%

CY2017Q4

teva

Term Loan Usd2 Point5 Billion1

TermLoanUSD2Point5Billion1

LIBOR +1.1375%

CY2017Q4

teva

Term Loan Usd2 Point5 Billion2

TermLoanUSD2Point5Billion2

LIBOR +1.50%

CY2017Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Two

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

4010000000

USD

CY2017Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Three

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

4295000000

USD

CY2017Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Four

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

4207000000

USD

CY2017

teva

Revenuerecognitiontextblock

<div><table style='border-collapse:collapse;' ><tr style='height:15pt;' ><td colspan='6' rowspan='1' style='width:444.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:444.75pt;' >NOTE 9—SALES RESERVES AND ALLOWANCES:</td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td></tr><tr style='height:4.5pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td></tr><tr style='height:15pt;' ><td colspan='9' rowspan='1' style='width:525pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:525pt;' > Sales reserves and allowances consisted of the following:</td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td colspan='5' rowspan='1' style='width:147.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:147.75pt;' >December 31,</td></tr><tr style='height:0.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td style='width:8.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td></tr><tr style='height:12.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td colspan='2' rowspan='1' style='width:67.5pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:67.5pt;' >2017</td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td colspan='2' rowspan='1' style='width:69.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:69.75pt;' >2016</td></tr><tr style='height:0.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td style='width:8.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td colspan='5' rowspan='1' style='width:147.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:147.75pt;' >(U.S. $ in millions)</td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' >Rebates</td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' >$</td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >3,077</td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' >$</td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >3,482</td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' >Medicaid and other governmental allowances</td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >1,908</td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >1,729</td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' >Chargebacks</td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >1,849</td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >1,584</td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' >Returns</td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >780</td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >844</td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' >Other</td><td style='width:8.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >267</td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;border-bottom-style:solid;border-bottom-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >200</td></tr><tr style='height:15.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' > </td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td style='width:8.25pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' >$</td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >7,881</td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' >$</td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >7,839</td></tr><tr style='height:15.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td style='width:8.25pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td></tr></table></div>

CY2017

teva

Salesreservesandallowancescurrenttextblock

<div><table style='border-collapse:collapse;' ><tr style='height:15pt;' ><td colspan='6' rowspan='1' style='width:444.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:444.75pt;' >NOTE 9—SALES RESERVES AND ALLOWANCES:</td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td></tr><tr style='height:4.5pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td></tr><tr style='height:15pt;' ><td colspan='9' rowspan='1' style='width:525pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:525pt;' > Sales reserves and allowances consisted of the following:</td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td colspan='5' rowspan='1' style='width:147.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:147.75pt;' >December 31,</td></tr><tr style='height:0.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td style='width:8.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td></tr><tr style='height:12.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td colspan='2' rowspan='1' style='width:67.5pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:67.5pt;' >2017</td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td colspan='2' rowspan='1' style='width:69.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:69.75pt;' >2016</td></tr><tr style='height:0.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td style='width:8.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td colspan='5' rowspan='1' style='width:147.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:147.75pt;' >(U.S. $ in millions)</td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' >Rebates</td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' >$</td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >3,077</td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' >$</td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >3,482</td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' >Medicaid and other governmental allowances</td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >1,908</td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >1,729</td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' >Chargebacks</td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >1,849</td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >1,584</td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' >Returns</td><td style='width:8.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >780</td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >844</td></tr><tr style='height:15pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td colspan='3' rowspan='1' style='width:342pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:342pt;' >Other</td><td style='width:8.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >267</td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;border-bottom-style:solid;border-bottom-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >200</td></tr><tr style='height:15.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' > </td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td style='width:8.25pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' >$</td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >7,881</td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' >$</td><td style='width:59.25pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:59.25pt;' >7,839</td></tr><tr style='height:15.75pt;' ><td style='width:35.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:35.25pt;' ></td><td style='width:107.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:107.25pt;' ></td><td style='width:103.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:103.5pt;' ></td><td style='width:131.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:131.25pt;' ></td><td style='width:8.25pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:8.25pt;' ></td><td style='width:59.25pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:10.5pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:59.25pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:59.25pt;' ></td></tr></table></div>

CY2016Q4

teva

Accrued Severance Pay Noncurrent

AccruedSeverancePayNoncurrent

120000000

USD

CY2016Q4

teva

Employee Related Obligations Noncurrent

EmployeeRelatedObligationsNoncurrent

317000000

USD

CY2017Q4

teva

Accrued Severance Pay Noncurrent

AccruedSeverancePayNoncurrent

91000000

USD

CY2017Q4

teva

Employee Related Obligations Noncurrent

EmployeeRelatedObligationsNoncurrent

273000000

USD

CY2017Q4

us-gaap

Defined Benefit Plan Accumulated Benefit Obligation

DefinedBenefitPlanAccumulatedBenefitObligation

182000000

USD

CY2016Q4

us-gaap

Defined Benefit Plan Accumulated Benefit Obligation

DefinedBenefitPlanAccumulatedBenefitObligation

197000000

USD

CY2017Q4

teva

Future Expected Domestic Minimum Benefit Payments Year One

FutureExpectedDomesticMinimumBenefitPaymentsYearOne

7000000

USD

CY2017Q4

teva

Future Expected Domestic Minimum Benefit Payments Year Two

FutureExpectedDomesticMinimumBenefitPaymentsYearTwo

7000000

USD

CY2017Q4

teva

Future Expected Domestic Minimum Benefit Payments Year Three

FutureExpectedDomesticMinimumBenefitPaymentsYearThree

8000000

USD

CY2017Q4

teva

Future Expected Domestic Minimum Benefit Payments Year Four

FutureExpectedDomesticMinimumBenefitPaymentsYearFour

9000000

USD

CY2017Q4

teva

Future Expected Domestic Minimum Benefit Payments Year Five

FutureExpectedDomesticMinimumBenefitPaymentsYearFive

10000000

USD

CY2017Q4

teva

Future Expected Domestic Minimum Benefit Payments Years Six Through Ten

FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen

53000000

USD

CY2016Q4

teva

Long Term Investments Earmarked For Domestic Severance Obligations

LongTermInvestmentsEarmarkedForDomesticSeveranceObligations

152000000

USD

CY2017Q4

us-gaap

Defined Benefit Plans Estimated Future Employer Contributions In Next Fiscal Year

DefinedBenefitPlansEstimatedFutureEmployerContributionsInNextFiscalYear

156000000

USD

CY2017Q4

us-gaap

Debt Instrument Maturity Date

DebtInstrumentMaturityDate

2026-01-01

CY2017Q4

teva

Termloan Gbp

TermloanGBP

0

USD

CY2017Q4

teva

Termloan Jpy1

TermloanJPY1

0

USD

CY2017Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

2880000000

USD

CY2016Q4

teva

Termloan Gbp

TermloanGBP

629000000

USD

CY2016Q4

teva

Termloan Jpy1

TermloanJPY1

68000000

USD

CY2016Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

810000000

USD

CY2016Q4

us-gaap

Senior Notes

SeniorNotes

27265000000

USD

CY2017Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Five

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive

1743000000

USD

CY2017Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal After Year Five

LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive

14680000000

USD

CY2015Q4

teva

Line Of Credit Facility

LineOfCreditFacility

3000000000

USD

CY2016Q4

teva

Line Of Credit Facility

LineOfCreditFacility

4500000000

USD

CY2016Q4

teva

Fixed Rate Senior Notes

FixedRateSeniorNotes

2.4

pure

CY2016Q4

teva

Term Loan Usd2 Point5 B

TermLoanUSD2Point5B

2500000000

USD

CY2017Q4

us-gaap

Operating Leases Future Minimum Payments Due Current

OperatingLeasesFutureMinimumPaymentsDueCurrent

160000000

USD

CY2017Q4

us-gaap

Operating Leases Future Minimum Payments Due In Three Years

OperatingLeasesFutureMinimumPaymentsDueInThreeYears

100000000

USD

CY2017Q4

us-gaap

Operating Leases Future Minimum Payments Due In Four Years

OperatingLeasesFutureMinimumPaymentsDueInFourYears

73000000

USD

CY2017Q4

us-gaap

Operating Leases Future Minimum Payments Due In Five Years

OperatingLeasesFutureMinimumPaymentsDueInFiveYears

51000000

USD

CY2017

us-gaap

Lease And Rental Expense

LeaseAndRentalExpense

200000000

USD

CY2016

us-gaap

Lease And Rental Expense

LeaseAndRentalExpense

164000000

USD

CY2015

us-gaap

Lease And Rental Expense

LeaseAndRentalExpense

122000000

USD

CY2012

teva

Opana Net Sales

OpanaNetSales

299000000

USD

CY2015Q4

teva

Modafinil Payment

ModafinilPayment

1200000000

USD

CY2015Q4

teva

Andro Gel Annual Sales

AndroGelAnnualSales

1050000000

USD

CY2016Q4

teva

Rugby Stettlement

RugbyStettlement

225000000

USD

CY2010Q3

teva

Annual Sales Of Effexor

AnnualSalesOfEffexor

2600000000

USD

CY2005Q1

teva

Annual Sales Of Lamictal

AnnualSalesOfLamictal

950000000

USD

CY2008Q3

teva

Annual Sales Of Lamictal

AnnualSalesOfLamictal

2300000000

USD

CY2005Q2

teva

Annual Sales Of Niaspan

AnnualSalesOfNiaspan

416000000

USD

CY2013Q3

teva

Annual Sales Of Niaspan

AnnualSalesOfNiaspan

1100000000

USD

CY2008Q3

teva

Annual Sales Of Aggrenox

AnnualSalesOfAggrenox

340000000

USD

CY2017

teva

Annual Sales Of Aggrenox

AnnualSalesOfAggrenox

455000000

USD

CY2010

teva

Annual Sales Of Actos

AnnualSalesOfActos

3700000000

USD

CY2010

teva

Annual Sales Of Actoplus

AnnualSalesOfActoplus

500000000

USD

CY2012Q3

teva

Annual Sales Of Actos

AnnualSalesOfActos

2800000000

USD

CY2012Q3

teva

Annual Sales Of Actoplus

AnnualSalesOfActoplus

430000000

USD

CY2015

teva

Nexium Settlement Payment

NexiumSettlementPayment

24000000

USD

CY2017

teva

Annual Sales Of Namebda

AnnualSalesOfNamebda

1400000000

USD

CY2009Q4

teva

Annual Sales Of Namebda

AnnualSalesOfNamebda

1100000000

USD

CY2013Q4

teva

Compensatory Damages And Penalties

CompensatoryDamagesAndPenalties

12400000

USD

CY2014Q1

teva

Punitive Damages

PunitiveDamages

17900000

USD

CY2017

teva

Compensatory Damages For State Of Illonois

CompensatoryDamagesForStateOfIllonois

100000000

USD

CY2015Q4

teva

Annual Sales Of Androgel At Time Of Sttlement

AnnualSalesOfAndrogelAtTimeOfSttlement

350000000

USD

CY2015Q4

teva

Annual Sales Of Androgel

AnnualSalesOfAndrogel

140000000

USD

CY2016Q4

teva

Ciprofloxacin Settlement

CiprofloxacinSettlement

225000000

USD

CY2017Q4

teva

Annual Sales Of Lidoderm

AnnualSalesOfLidoderm

1200000000

USD

CY2013Q4

teva

Annual Sales Of Lidoderm

AnnualSalesOfLidoderm

1400000000

USD

CY2016Q4

teva

Annual Sales Of Intuniv

AnnualSalesOfIntuniv

335000000

USD

CY2014Q4

teva

Annual Sales Of Intuniv

AnnualSalesOfIntuniv

327000000

USD

CY2016

teva

Fcpa Settlement

FcpaSettlement

519000000

USD

CY2016

us-gaap

Treasury Stock Shares Acquired

TreasuryStockSharesAcquired

0

shares

CY2017

us-gaap

Treasury Stock Shares Acquired

TreasuryStockSharesAcquired

0

shares

CY2015

us-gaap

Treasury Stock Shares Acquired

TreasuryStockSharesAcquired

7700000

shares

CY2016

us-gaap

Other Comprehensive Income Loss Derivatives Qualifying As Hedges Tax

OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax

0

USD

CY2016

us-gaap

Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax

OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax

-477000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments And Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax

-26000000

USD

CY2017

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

5.7

CY2016

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

9.4

CY2015

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

10.9

CY2017

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P5Y0M0D

CY2016

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P5Y0M0D

CY2015

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P5Y0M0D

CY2017Q4

us-gaap

Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options

ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions

43121000

shares

CY2017Q4

teva

Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2010

ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010

7.3

pure

CY2017Q4

teva

Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance2010

ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010

44.32

CY2017Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

7400000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans Before Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax

-6000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax

32000000

USD

CY2017

us-gaap

Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax

OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax

1075000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax

-378000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

1453000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

0

USD

CY2014Q4

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-1283000000

USD

CY2014Q4

us-gaap

Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-7000000

USD

CY2014Q4

us-gaap

Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax

AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax

40000000

USD

CY2015Q4

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-2384000000

USD

CY2015Q4

us-gaap

Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

312000000

USD

CY2015Q4

us-gaap

Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax

AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax

175000000

USD

CY2016Q4

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-2769000000

USD

CY2016Q4

us-gaap

Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-7000000

USD

CY2016Q4

us-gaap

Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax

AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax

-302000000

USD

CY2017Q4

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-1316000000

USD

CY2017Q4

us-gaap

Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-4000000

USD

CY2017Q4

us-gaap

Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax

AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax

-442000000

USD

CY2015

us-gaap

Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax

OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax

-1131000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax

-24000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

-1107000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

-6000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments And Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax

-413000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax

-737000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax

324000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax

5000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

319000000

USD

CY2015

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax

137000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Before Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax

2000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax

OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax

135000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Derivatives Qualifying As Hedges Tax

OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax

0

USD

CY2015

us-gaap

Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax

OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax

135000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments And Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax

33000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans Before Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax

4000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax

-37000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax

-2000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-35000000

USD

CY2015

teva

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax1

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax1

-1101000000

USD

CY2016

us-gaap

Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax

OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax

-355000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax

-3000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

-352000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

33000000

USD

CY2016

teva

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax1

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax1

-385000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments And Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax

-456000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax

-140000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax

-316000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax

3000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-319000000

USD

CY2016

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax

-491000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Before Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax

-14000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax

OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax

-477000000

USD

CY2017

teva

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax1

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax1

1453000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments And Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax

64000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax

66000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax

-2000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax

-5000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

3000000

USD

CY2017

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax

-167000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Before Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax

-27000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax

OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax

-140000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Derivatives Qualifying As Hedges Tax

OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax

0

USD

CY2017

us-gaap

Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax

OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax

-140000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments And Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax

-3000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans Before Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax

-5000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax

8000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax

-2000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

10000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax

9000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

23000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Before Reclassifications Before Tax

OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax

-1374000000

USD

CY2015

teva

Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax Total

ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTaxTotal

-763000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Before Tax

OtherComprehensiveIncomeLossBeforeTax

-611000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-1000000

USD

CY2015

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-612000000

USD

CY2014Q4

teva

Accumulated Other Comprehensive Income Loss Other Adjustments

AccumulatedOtherComprehensiveIncomeLossOtherAdjustments

-93000000

USD

CY2015Q4

teva

Accumulated Other Comprehensive Income Loss Other Adjustments

AccumulatedOtherComprehensiveIncomeLossOtherAdjustments

-58000000

USD

CY2016Q4

teva

Accumulated Other Comprehensive Income Loss Other Adjustments

AccumulatedOtherComprehensiveIncomeLossOtherAdjustments

-81000000

USD

CY2017Q4

teva

Accumulated Other Comprehensive Income Loss Other Adjustments

AccumulatedOtherComprehensiveIncomeLossOtherAdjustments

-91000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Before Reclassifications Before Tax

OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax

-1328000000

USD

CY2016

teva

Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax Total

ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTaxTotal

-151000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Before Tax

OtherComprehensiveIncomeLossBeforeTax

-1177000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-27000000

USD

CY2016

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-1204000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Before Reclassifications Before Tax

OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax

969000000

USD

CY2017

teva

Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax Total

ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTaxTotal

-334000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Before Tax

OtherComprehensiveIncomeLossBeforeTax

1303000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

3000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

1306000000

USD

CY2016Q4

teva

Closing Market Price Of Company Common Stock

ClosingMarketPriceOfCompanyCommonStock

36.25

CY2017

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

5000000

USD

CY2016

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

120000000

USD

CY2015

teva

Average Market Price Of Company Common Stock During Period

AverageMarketPriceOfCompanyCommonStockDuringPeriod

61.66

CY2017

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

1.36

CY2016

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

1.36

CY2016

teva

Average Market Price Of Company Common Stock During Period

AverageMarketPriceOfCompanyCommonStockDuringPeriod

50.96

CY2017

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights

ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights

The vesting period of the outstanding options, RSUs and PSUs is generally 1 to 4 years from the date of grant. The rights of the ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of the other ordinary shares of the Company. The contractual term of these options is primarily for seven years in prior plans and ten years for options granted under the 2010 plan described above.

CY2016Q1

us-gaap

Proceeds From Issuance Of Preferred Stock And Preference Stock

ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

329000000

USD

CY2017

us-gaap

Convertible Preferred Stock Terms Of Conversion

ConvertiblePreferredStockTermsOfConversion

13.3 and 16.0000

CY2016Q4

us-gaap

Convertible Preferred Stock Shares Issued Upon Conversion

ConvertiblePreferredStockSharesIssuedUponConversion

337500

shares

CY2016Q1

teva

Aggregate Proceeds From Issuance Of Preferred Stock And Preference Stock

AggregateProceedsFromIssuanceOfPreferredStockAndPreferenceStock

3620000000

USD

CY2017

us-gaap

Preferred Stock Dividend Rate Per Dollar Amount

PreferredStockDividendRatePerDollarAmount

1000

CY2014Q4

us-gaap

Stock Repurchase Program Authorized Amount1

StockRepurchaseProgramAuthorizedAmount1

3000000000

USD

CY2015Q4

us-gaap

Share Price

SharePrice

62.5

CY2015Q4

teva

Equivalent Share Units Approval For Grant

EquivalentShareUnitsApprovalForGrant

43700000

shares

CY2016Q4

teva

Accrued Dividednds Payable

AccruedDividedndsPayable

11000000

USD

CY2016Q4

teva

Convertible Preferred Shares Rate

ConvertiblePreferredSharesRate

7

pure

CY2015

teva

Adss Offering

AdssOffering

54000000

shares

CY2016

teva

Shares Transferred To Allergan

SharesTransferredToAllergan

100300000

shares

CY2016Q4

teva

Dividend Mandatory Convertible Preferred Shares

DividendMandatoryConvertiblePreferredShares

71.56

CY2017

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

1451000000

USD

CY2016

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

1516000000

USD

CY2015

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

1932000000

USD

CY2017

us-gaap

Income Loss From Continuing Operations Before Income Taxes Foreign

IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign

-19830000000

USD

CY2016

us-gaap

Income Loss From Continuing Operations Before Income Taxes Foreign

IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign

-692000000

USD

CY2015

us-gaap

Income Loss From Continuing Operations Before Income Taxes Foreign

IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign

420000000

USD

CY2017

us-gaap

Federal Income Tax Expense Benefit Continuing Operations

FederalIncomeTaxExpenseBenefitContinuingOperations

96000000

USD

CY2017

us-gaap

Foreign Income Tax Expense Benefit Continuing Operations

ForeignIncomeTaxExpenseBenefitContinuingOperations

-2029000000

USD

CY2016

us-gaap

Federal Income Tax Expense Benefit Continuing Operations

FederalIncomeTaxExpenseBenefitContinuingOperations

209000000

USD

CY2016

us-gaap

Foreign Income Tax Expense Benefit Continuing Operations

ForeignIncomeTaxExpenseBenefitContinuingOperations

312000000

USD

CY2015

us-gaap

Federal Income Tax Expense Benefit Continuing Operations

FederalIncomeTaxExpenseBenefitContinuingOperations

149000000

USD

CY2015

us-gaap

Foreign Income Tax Expense Benefit Continuing Operations

ForeignIncomeTaxExpenseBenefitContinuingOperations

485000000

USD

CY2017

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

373000000

USD

CY2017

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-2306000000

USD

CY2016

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

481000000

USD

CY2016

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

40000000

USD

CY2015

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

298000000

USD

CY2015

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

336000000

USD

CY2015

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.265

pure

CY2016

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.25

pure

CY2017

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.24

pure

CY2017

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

-4411000000

USD

CY2016

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

206000000

USD

CY2015

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

623000000

USD

CY2015

us-gaap

Income Tax Reconciliation Change In Enacted Tax Rate

IncomeTaxReconciliationChangeInEnactedTaxRate

-337000000

USD

CY2016

us-gaap

Income Tax Reconciliation Change In Enacted Tax Rate

IncomeTaxReconciliationChangeInEnactedTaxRate

-212000000

USD

CY2017

us-gaap

Income Tax Reconciliation Change In Enacted Tax Rate

IncomeTaxReconciliationChangeInEnactedTaxRate

-253000000

USD

CY2015

us-gaap

Income Tax Reconciliation Foreign Income Tax Rate Differential

IncomeTaxReconciliationForeignIncomeTaxRateDifferential

447000000

USD

CY2016

us-gaap

Income Tax Reconciliation Foreign Income Tax Rate Differential

IncomeTaxReconciliationForeignIncomeTaxRateDifferential

546000000

USD

CY2017

us-gaap

Income Tax Reconciliation Foreign Income Tax Rate Differential

IncomeTaxReconciliationForeignIncomeTaxRateDifferential

3817000000

USD

CY2016

us-gaap

Income Tax Reconciliation Tax Contingencies

IncomeTaxReconciliationTaxContingencies

-19000000

USD

CY2015

us-gaap

Income Tax Reconciliation Tax Contingencies

IncomeTaxReconciliationTaxContingencies

-99000000

USD

CY2016Q4

us-gaap

Deferred Tax Liabilities Property Plant And Equipment

DeferredTaxLiabilitiesPropertyPlantAndEquipment

312000000

USD

CY2016Q4

teva

Deferred Tax Assets Carryforward Losses And Deductions Noncurrent

DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent

1922000000

USD

CY2016Q4

us-gaap

Deferred Tax Liabilities Goodwill And Intangible Assets

DeferredTaxLiabilitiesGoodwillAndIntangibleAssets

5569000000

USD

CY2016Q4

teva

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Noncurrent

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNoncurrent

108000000

USD

CY2016Q4

teva

Deferred Tax Assets Liabilities Other Net Noncurrent

DeferredTaxAssetsLiabilitiesOtherNetNoncurrent

-163000000

USD

CY2016Q4

teva

Deferred Tax Assets Liabilities Gross Noncurrent

DeferredTaxAssetsLiabilitiesGrossNoncurrent

3099000000

USD

CY2016Q4

us-gaap

Deferred Tax Assets Valuation Allowance Noncurrent

DeferredTaxAssetsValuationAllowanceNoncurrent

1689000000

USD

CY2016Q4

us-gaap

Deferred Tax Assets Liabilities Net Noncurrent

DeferredTaxAssetsLiabilitiesNetNoncurrent

-4788000000

USD

CY2017Q4

teva

Inventory Related

InventoryRelated

-40000000

USD

CY2017Q4

teva

Sales Reserves And Allowance

SalesReservesAndAllowance

-201000000

USD

CY2017Q4

teva

Provision For Legal Settlements

ProvisionForLegalSettlements

-171000000

USD

CY2017Q4

us-gaap

Deferred Tax Liabilities Goodwill And Intangible Assets

DeferredTaxLiabilitiesGoodwillAndIntangibleAssets

3132000000

USD

CY2017Q4

teva

Deferred Tax Assets Carryforward Losses And Deductions Noncurrent

DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent

1485000000

USD

CY2017Q4

us-gaap

Deferred Tax Liabilities Property Plant And Equipment

DeferredTaxLiabilitiesPropertyPlantAndEquipment

231000000

USD

CY2017Q4

teva

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Noncurrent

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNoncurrent

142000000

USD

CY2017Q4

teva

Deferred Tax Assets Liabilities Other Net Noncurrent

DeferredTaxAssetsLiabilitiesOtherNetNoncurrent

-125000000

USD

CY2017Q4

teva

Deferred Tax Assets Liabilities Gross Noncurrent

DeferredTaxAssetsLiabilitiesGrossNoncurrent

1199000000

USD

CY2017Q4

us-gaap

Deferred Tax Assets Valuation Allowance Noncurrent

DeferredTaxAssetsValuationAllowanceNoncurrent

1504000000

USD

CY2017Q4

us-gaap

Deferred Tax Assets Liabilities Net Noncurrent

DeferredTaxAssetsLiabilitiesNetNoncurrent

-2703000000

USD

CY2016Q4

us-gaap

Deferred Tax Assets Liabilities Net

DeferredTaxAssetsLiabilitiesNet

-4788000000

USD

CY2017

us-gaap

Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions

56000000

USD

CY2017

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

26000000

USD

CY2017

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities

UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities

-56000000

USD

CY2017

teva

Unrecognized Tax Benefits Of Acquirees Added In Period

UnrecognizedTaxBenefitsOfAcquireesAddedInPeriod

273000000

USD

CY2017

teva

Unrecognized Tax Benefits Increases Decreases Other

UnrecognizedTaxBenefitsIncreasesDecreasesOther

1000000

USD

CY2016Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

734000000

USD

CY2015Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

648000000

USD

CY2014Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

713000000

USD

CY2016

us-gaap

Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions

23000000

USD

CY2016

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

71000000

USD

CY2016

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities

UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities

-103000000

USD

CY2016

teva

Unrecognized Tax Benefits Of Acquirees Added In Period

UnrecognizedTaxBenefitsOfAcquireesAddedInPeriod

101000000

USD

CY2016

teva

Unrecognized Tax Benefits Increases Decreases Other

UnrecognizedTaxBenefitsIncreasesDecreasesOther

-6000000

USD

CY2015

us-gaap

Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions

-6000000

USD

CY2015

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

43000000

USD

CY2015

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities

UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities

-99000000

USD

CY2015

teva

Unrecognized Tax Benefits Of Acquirees Added In Period

UnrecognizedTaxBenefitsOfAcquireesAddedInPeriod

0

USD

CY2015

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities

631000000

USD

CY2015

teva

Unrecognized Tax Benefits Increases Decreases Other

UnrecognizedTaxBenefitsIncreasesDecreasesOther

-3000000

USD

CY2017Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

1034000000

USD

CY2017Q4

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

112000000

USD

CY2015Q4

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

101000000

USD

CY2016Q4

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

83000000

USD

CY2017Q4

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

29000000

USD

CY2016Q4

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

-18000000

USD

CY2015Q4

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

14000000

USD

CY2017Q4

teva

Amendment Payment69

AmendmentPayment69

577000000

USD

CY2017Q4

teva

Exemptincome

9400000000

USD

CY2016Q4

us-gaap

Accounts Receivable From Securitization

AccountsReceivableFromSecuritization

621000000

USD

CY2017

us-gaap

Proceeds From Accounts Receivable Securitization

ProceedsFromAccountsReceivableSecuritization

4944000000

USD

CY2017

us-gaap

Repayments Of Accounts Receivable Securitization

RepaymentsOfAccountsReceivableSecuritization

4863000000

USD

CY2017

teva

Effect Of Exchange Rate On Accounts Receivable From Securitization

EffectOfExchangeRateOnAccountsReceivableFromSecuritization

97000000

USD

CY2015Q4

us-gaap

Accounts Receivable From Securitization

AccountsReceivableFromSecuritization

445000000

USD

CY2016

us-gaap

Proceeds From Accounts Receivable Securitization

ProceedsFromAccountsReceivableSecuritization

3784000000

USD

CY2016

us-gaap

Repayments Of Accounts Receivable Securitization

RepaymentsOfAccountsReceivableSecuritization

3660000000

USD

CY2016

teva

Effect Of Exchange Rate On Accounts Receivable From Securitization

EffectOfExchangeRateOnAccountsReceivableFromSecuritization

52000000

USD

CY2017

teva

Schedule Of Account Receivable From Securitization Tabletextblock

ScheduleOfAccountReceivableFromSecuritizationTabletextblock

<div><table style='border-collapse:collapse;' ><tr style='height:24pt;' ><td style='width:30pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:30pt;' ></td><td style='width:282.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:282.75pt;' ></td><td style='width:6.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:6.75pt;' ></td><td colspan='5' rowspan='1' style='width:143.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:143.25pt;' >As of and for the year ended December 31,</td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td></tr><tr style='height:0.75pt;' ><td style='width:30pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:30pt;' ></td><td style='width:282.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:282.75pt;' ></td><td style='width:6.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:6.75pt;' ></td><td style='width:12.75pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:12.75pt;' ></td><td style='width:57pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:57pt;' ></td><td style='width:3.75pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:12.75pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:12.75pt;' ></td><td style='width:57pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:57pt;' ></td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td></tr><tr style='height:10.5pt;' ><td style='width:30pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:30pt;' ></td><td style='width:282.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:282.75pt;' ></td><td style='width:6.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:6.75pt;' ></td><td colspan='2' rowspan='1' style='width:69.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:69.75pt;' >2017</td><td style='width:3.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td colspan='2' rowspan='1' style='width:69.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:69.75pt;' >2016</td><td style='width:3.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td></tr><tr style='height:10.5pt;' ><td style='width:30pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:30pt;' ></td><td style='width:282.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:282.75pt;' ></td><td style='width:6.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:6.75pt;' ></td><td colspan='5' rowspan='1' style='width:143.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:143.25pt;' >(U.S. $ in millions)</td><td style='width:3.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td></tr><tr style='height:0.75pt;' ><td style='width:30pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:30pt;' ></td><td style='width:282.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:282.75pt;' ></td><td style='width:6.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:6.75pt;' ></td><td style='width:12.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:12.75pt;' ></td><td style='width:57pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:57pt;' ></td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:12.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:12.75pt;' ></td><td style='width:57pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:57pt;' ></td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td></tr><tr style='height:15pt;' ><td style='width:30pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:30pt;' ></td><td style='width:282.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:282.75pt;' >Sold receivables at the beginning of the year </td><td style='width:6.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:6.75pt;' ></td><td style='width:12.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:12.75pt;' >$</td><td style='width:57pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:57pt;' >621</td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:12.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:12.75pt;' >$</td><td style='width:57pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:57pt;' >445</td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td></tr><tr style='height:15pt;' ><td style='width:30pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:30pt;' ></td><td style='width:282.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:282.75pt;' >Proceeds from sale of receivables</td><td style='width:6.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:6.75pt;' ></td><td style='width:12.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:12.75pt;' ></td><td style='width:57pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:57pt;' >4,944</td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:12.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:12.75pt;' ></td><td style='width:57pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:57pt;' >3,784</td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td></tr><tr style='height:15pt;' ><td style='width:30pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:30pt;' ></td><td style='width:282.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:282.75pt;' >Cash collections (remitted to the owner of the receivables)</td><td style='width:6.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:6.75pt;' ></td><td style='width:12.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:12.75pt;' ></td><td style='width:57pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:57pt;' >(4,863)</td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:12.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:12.75pt;' ></td><td style='width:57pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:57pt;' >(3,660)</td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td></tr><tr style='height:15pt;' ><td style='width:30pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:30pt;' ></td><td style='width:282.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:282.75pt;' >Effect of currency exchange rate changes</td><td style='width:6.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:6.75pt;' ></td><td style='width:12.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:12.75pt;' ></td><td style='width:57pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:57pt;' >97</td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:12.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:12.75pt;' ></td><td style='width:57pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:57pt;' >52</td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td></tr><tr style='height:15.75pt;' ><td style='width:30pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:30pt;' ></td><td style='width:282.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:282.75pt;' >Sold receivables at the end of the year</td><td style='width:6.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:6.75pt;' ></td><td style='width:12.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:12.75pt;' >$</td><td style='width:57pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:57pt;' >799</td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:12.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:12.75pt;' >$</td><td style='width:57pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:57pt;' >621</td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td></tr></table></div>

CY2016

teva

Cash Flow Hedge Of Anticipated Future Debt Issuance

CashFlowHedgeOfAnticipatedFutureDebtIssuance

1500000000

USD

CY2015

teva

Cash Flow Hedge Of Anticipated Future Debt Issuance

CashFlowHedgeOfAnticipatedFutureDebtIssuance

3750000000

USD

CY2016Q4

teva

Settlement Gain Position

SettlementGainPosition

41000000

USD

CY2016Q4

teva

Interest Rate Swap Gain

InterestRateSwapGain

2000000

USD

CY2016Q4

teva

Tevaothercomprehensiveloss

493000000

USD

CY2017Q4

teva

Revenues Other Than Usd

RevenuesOtherThanUsd

44

pure

CY2017

us-gaap

Interest Expense

InterestExpense

875000000

USD

CY2017

us-gaap

Investment Income Nonoperating

InvestmentIncomeNonoperating

84000000

USD

CY2017

us-gaap

Foreign Currency Transaction Gain Loss Before Tax

ForeignCurrencyTransactionGainLossBeforeTax

-65000000

USD

CY2016

us-gaap

Interest Expense

InterestExpense

546000000

USD

CY2016

us-gaap

Investment Income Nonoperating

InvestmentIncomeNonoperating

51000000

USD

CY2016

us-gaap

Foreign Currency Transaction Gain Loss Before Tax

ForeignCurrencyTransactionGainLossBeforeTax

49000000

USD

CY2015

us-gaap

Interest Expense

InterestExpense

270000000

USD

CY2015

us-gaap

Investment Income Nonoperating

InvestmentIncomeNonoperating

34000000

USD

CY2015

us-gaap

Foreign Currency Transaction Gain Loss Before Tax

ForeignCurrencyTransactionGainLossBeforeTax

9000000

USD

CY2017

teva

Gain Loss Recognized In Earnings From Hedging Foreign Currency Risk Of Business Combination Purchase Price Obligation

GainLossRecognizedInEarningsFromHedgingForeignCurrencyRiskOfBusinessCombinationPurchasePriceObligation

0

USD

CY2016

teva

Gain Loss Recognized In Earnings From Hedging Foreign Currency Risk Of Business Combination Purchase Price Obligation

GainLossRecognizedInEarningsFromHedgingForeignCurrencyRiskOfBusinessCombinationPurchasePriceObligation

0

USD

CY2017

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities

0

USD

CY2016

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities

136000000

USD

CY2017

teva

Gain From Interest Rate Swap Transaction

GainFromInterestRateSwapTransaction

0

USD

CY2017

teva

Other Finance Expenses

OtherFinanceExpenses

-3000000

USD

CY2016

teva

Other Finance Expenses

OtherFinanceExpenses

2000000

USD

CY2017

teva

Venezuela Devaluation

VenezuelaDevaluation

42000000

USD

CY2016

teva

Venezuela Devaluation

VenezuelaDevaluation

746000000

USD

CY2015

teva

Gain Loss Recognized In Earnings From Hedging Foreign Currency Risk Of Business Combination Purchase Price Obligation

GainLossRecognizedInEarningsFromHedgingForeignCurrencyRiskOfBusinessCombinationPurchasePriceObligation

0

USD

CY2015

teva

Gain From Interest Rate Swap Transaction

GainFromInterestRateSwapTransaction

0

USD

CY2015

teva

Other Finance Expenses

OtherFinanceExpenses

142000000

USD

CY2017

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

3782000000

USD

CY2016

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

746000000

USD

CY2015

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

361000000

USD

CY2017

teva

Impairment And Restructuring

ImpairmentAndRestructuring

5074000000

USD

CY2016

teva

Impairment And Restructuring

ImpairmentAndRestructuring

1419000000

USD

CY2015

teva

Impairment And Restructuring

ImpairmentAndRestructuring

1176000000

USD

CY2017

teva

Legal Settlements Loss Contingencies Impariments Other Expenses

LegalSettlementsLossContingenciesImparimentsOtherExpenses

102000000

USD

CY2016

teva

Legal Settlements Loss Contingencies Impariments Other Expenses

LegalSettlementsLossContingenciesImparimentsOtherExpenses

84000000

USD

CY2015

teva

Legal Settlements Loss Contingencies Impariments Other Expenses

LegalSettlementsLossContingenciesImparimentsOtherExpenses

12000000

USD

CY2017

us-gaap

Business Combination Acquisition Related Costs

BusinessCombinationAcquisitionRelatedCosts

105000000

USD

CY2016

us-gaap

Business Combination Acquisition Related Costs

BusinessCombinationAcquisitionRelatedCosts

261000000

USD

CY2016

us-gaap

Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1

BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

83000000

USD

CY2015

us-gaap

Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1

BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

399000000

USD

CY2015

us-gaap

Business Combination Acquisition Related Costs

BusinessCombinationAcquisitionRelatedCosts

221000000

USD

CY2015

us-gaap

Restructuring Charges

RestructuringCharges

183000000

USD

CY2016

us-gaap

Restructuring Charges

RestructuringCharges

245000000

USD

CY2017

teva

Restructuring And Impairment Textblock

RestructuringAndImpairmentTextblock

<div><table style='border-collapse:collapse;' ><tr style='height:14.25pt;' ><td colspan='9' rowspan='1' style='width:433.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:433.5pt;' >NOTE 18—OTHER EXPENSES:</td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:40.5pt;' ></td></tr><tr style='height:18pt;' ><td style='width:27pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:27pt;' ></td><td colspan='10' rowspan='1' style='width:458.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:458.25pt;' >a. Other assets impairments, restructuring and other items:</td></tr><tr style='height:18pt;' ><td style='width:27pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:27pt;' ></td><td style='width:26.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:26.25pt;' ></td><td colspan='9' rowspan='1' style='width:432pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:432pt;' >Other assets impairments, restructuring and other items consisted of the following:</td></tr><tr style='height:11.25pt;' ><td style='width:27pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:27pt;' ></td><td style='width:26.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:26.25pt;' ></td><td style='width:269.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:269.25pt;' > </td><td colspan='8' rowspan='1' style='width:162.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:162.75pt;' >Year ended December 31,</td></tr><tr style='height:12.75pt;' ><td style='width:27pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:27pt;' ></td><td style='width:26.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:26.25pt;' ></td><td style='width:269.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:269.25pt;' > </td><td colspan='2' rowspan='1' style='width:51.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:51.75pt;' >2017</td><td style='width:3.75pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td colspan='2' rowspan='1' style='width:51.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:51.75pt;' >2016</td><td style='width:3.75pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td colspan='2' rowspan='1' style='width:51.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:51.75pt;' >2015</td></tr><tr style='height:3pt;' ><td style='width:27pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:27pt;' ></td><td style='width:26.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:26.25pt;' ></td><td style='width:269.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:269.25pt;' ></td><td style='width:11.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:40.5pt;' ></td><td style='width:3.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:40.5pt;' ></td><td style='width:3.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:40.5pt;' ></td></tr><tr style='height:10.5pt;' ><td style='width:27pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:27pt;' ></td><td style='width:26.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:26.25pt;' ></td><td style='width:269.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:269.25pt;' ></td><td colspan='8' rowspan='1' style='width:162.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:162.75pt;' >(U.S. $ in millions)</td></tr><tr style='height:12.75pt;' ><td style='width:27pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:27pt;' ></td><td colspan='2' rowspan='1' style='width:295.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:295.5pt;' >Impairment of long-lived assets (see notes 6 and 8) (1)</td><td style='width:11.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:11.25pt;' >$</td><td style='width:40.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >3,782</td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:11.25pt;' >$</td><td style='width:40.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >746</td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:11.25pt;' >$</td><td style='width:40.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >361</td></tr><tr style='height:12.75pt;' ><td style='width:27pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:27pt;' ></td><td colspan='2' rowspan='1' style='width:295.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:295.5pt;' >Contingent consideration (see note 3)</td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >154</td><td style='width:3.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >83</td><td style='width:3.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >399</td></tr><tr style='height:12.75pt;' ><td style='width:27pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:27pt;' ></td><td colspan='2' rowspan='1' style='width:295.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:295.5pt;' >Acquisition, integration and related costs</td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >105</td><td style='width:3.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >261</td><td style='width:3.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >221</td></tr><tr style='height:12.75pt;' ><td style='width:27pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:27pt;' ></td><td colspan='2' rowspan='1' style='width:295.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:295.5pt;' >Restructuring</td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >535</td><td style='width:3.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >245</td><td style='width:3.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >183</td></tr><tr style='height:12.75pt;' ><td style='width:27pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:27pt;' ></td><td colspan='2' rowspan='1' style='width:295.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:295.5pt;' >Venezuela deconsolidation charge*</td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >396</td><td style='width:3.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >-</td><td style='width:3.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >-</td></tr><tr style='height:12.75pt;' ><td style='width:27pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:27pt;' ></td><td colspan='2' rowspan='1' style='width:295.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:295.5pt;' >Other</td><td style='width:11.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >102</td><td style='width:3.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >84</td><td style='width:3.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >12</td></tr><tr style='height:13.5pt;' ><td style='width:27pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:27pt;' ></td><td colspan='2' rowspan='1' style='width:295.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:295.5pt;' >Total</td><td style='width:11.25pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:11.25pt;' >$</td><td style='width:40.5pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >5,074</td><td style='width:3.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:11.25pt;' >$</td><td style='width:40.5pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >1,419</td><td style='width:3.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:11.25pt;' >$</td><td style='width:40.5pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:40.5pt;' >1,176</td></tr><tr style='height:3.75pt;' ><td style='width:27pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:27pt;' ></td><td style='width:26.25pt;border-bottom-style:solid;border-bottom-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:26.25pt;' ></td><td style='width:269.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:269.25pt;' > </td><td style='width:11.25pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:40.5pt;' > </td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:40.5pt;' ></td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:40.5pt;' ></td></tr><tr style='height:15pt;' ><td style='width:27pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:27pt;' ></td><td colspan='2' rowspan='1' style='width:295.5pt;border-top-style:solid;border-top-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:295.5pt;' >* Refer to note 1.</td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:40.5pt;' ></td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:40.5pt;' ></td><td style='width:3.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:3.75pt;' ></td><td style='width:11.25pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:11.25pt;' ></td><td style='width:40.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:40.5pt;' ></td></tr></table></div><div>(1) Including impairments related to exit and disposal activities ImpairmentsIn determining the estimated fair value of the long-lived assets, Teva utilized a discounted cash flow model. The key assumptions within the model related to forecasting future revenue and operating income, an appropriate weighted average cost of capital, and an appropriate terminal value based on the nature of the long-lived asset. The Company’s updated forecasts of net cash flows for the impaired assets reflect, among other things, the following: (i) for research and development in-process assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risks associated with these assets; and (ii) for product rights, pricing and volume projections as well as patent life and any significant changes to the competitive environment.As a result of Teva's plant rationalization acceleration, following the two year restructuring plan that was announced on December 14, 2017, to the extent the Company will change its plans on any given asset and/or the assumptions underlying such plan, there could be additional impairments in the future.In 2017 we recorded expenses of $5.1 billion for impairments, restructuring and others, compared to $1.4 billion of such expenses in 2016. The expenses in 2017 consisted of: Impairments of long-lived assets in 2017 were $3.8 billion, comprised of:(a) Identifiable IPR&D of $1.6 billion, primarily comprised of: (i) $838 million related to revaluation of generics products acquired from Actavis due to development progress, changes in other key valuation indications (market size, legal landscape or launch date); (ii) $390 million related to discontinued Actavis Generics products; (iii) $153 million related to discontinued Rimsa projects; and (iv) $188 million related to discontinued specialty products in the United States primarily LAMA/LABA from Microdose, in addition to reduction in value of reziluzamab following the results of the recent phase 3 clinical trial;(b) Identifiable product rights of $1.6 billion, primarily comprised of: (i) $583 million related to revaluation of Actavis Generics product rights in the United States (ii) $523 million related to Teva Takeda product and marketing rights for certain products; (iii) $390 million related to Actavis Generics product rights in Europe and ROW; and (iv) $47 million related to termination of VANTRELA product rights in the United States.Impairments of identifiable intangible assets were $589 million and $265 million in 2016 and 2015, respectively.(c) Impairments of property, plant and equipment were $544 million comprised of: (1) $382 million related to restructuring costs, mainly comprising: I. $156 million related to the planned closure of Teva’s facilities in Jerusalem, Israel; II. $144 million primarily related to plant and R&D rationalizations in Puerto Rico, New Jersey and Canada; and III. $69 million related to discontinued manufacturing activities at the Godollo, Hungary site during 2017, following company’s decision in the second quarter of 2017 to divest or close this facility. Teva previously recorded an impairment of $80 million for this facility in the fourth quarter of 2016. (2) Other impairment costs, mainly: I. $62 million related to site closures in Japan; andII. $42 million related to the sale of company’s Ra'anana, Israel site. Property, plant and equipment impairment was $149 million and $96 million in 2016 and 2015, respectively.Following an FDA audit of Teva’s active pharmaceutical ingredient (“API”) production facility in China in September 2016, Teva received a warning letter from the FDA in April 2017. Teva has undertaken corrective actions to address both the specific concerns raised by investigators as well as the underlying causes of those concerns and resumed shipments from this facility in May 2017. Teva has requested that the FDA conduct a follow-up inspection to close the warning letter. Contingent considerationIn 2017, Teva recorded $154 million of contingent consideration expenses, compared to $83 million in 2016. The expenses in 2017 consisted mainly of $178 million related to BENDEKA in connection with royalty accruals, $40 million related to re-evaluation of a Labrys project, partially offset by a $89 million reversal of contingent consideration related to a cancelled LAMA/LABA (MicroDose) project. Acquisition, integration and related costsIn 2017, Teva recorded $105 million of acquisition and integration expenses, compared to $261 million in 2016. The expenses in 2017 mainly consisted of expenses related to the acquisition and integration of Actavis Generics.Restructuring In 2017, Teva recorded $535 million of restructuring expenses, compared to $245 million in 2016. The expenses in 2017 were primarily related to Teca network restructuring plan, which seeks to further optimize and consolidate its manufacturing footprint and restructure its generic R&D network. In addition Teva incurred restructuring expenses in connection with the acquisition of Actavis Generics. In addition Teva recorded $382 million impairment of PP&E related to restructuring costs as detailed in "— Impairments" above.The following table provides the components of costs associated with Teva's restructuring plan including costs related to exit and disposal activities:</div><div><table style='border-collapse:collapse;' ><tr style='height:14.25pt;' ><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:114pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:114pt;' > </td><td colspan='8' rowspan='1' style='width:211.5pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:211.5pt;' >Year ended December 31,</td></tr><tr style='height:14.25pt;' ><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:114pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:114pt;' > </td><td colspan='2' rowspan='1' style='width:63.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:63.75pt;' >2017</td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td colspan='2' rowspan='1' style='width:63.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:63.75pt;' >2016</td><td style='width:10.5pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td colspan='2' rowspan='1' style='width:63.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:63.75pt;' >2015</td></tr><tr style='height:4.5pt;' ><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:114pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:114pt;' ></td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:9.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td></tr><tr style='height:14.25pt;' ><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:114pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:114pt;' ></td><td colspan='8' rowspan='1' style='width:211.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:211.5pt;' >(U.S. $ in millions)</td></tr><tr style='height:14.25pt;' ><td colspan='2' rowspan='1' style='width:168pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:168pt;' >Restructuring</td><td style='width:9.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:9.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:9.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:9.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td></tr><tr style='height:14.25pt;' ><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:114pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:114pt;' >Employee termination</td><td style='width:9.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' >$</td><td style='width:54pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >443</td><td style='width:9.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:9.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' >$</td><td style='width:54pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >211</td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:9.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' >$</td><td style='width:54pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >183</td></tr><tr style='height:14.25pt;' ><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:114pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:114pt;' >Other</td><td style='width:9.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >92</td><td style='width:9.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:9.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >34</td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:9.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >-</td></tr><tr style='height:15pt;' ><td colspan='2' rowspan='1' style='width:168pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:168pt;' >Total</td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' >$</td><td style='width:54pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >535</td><td style='width:9.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' >$</td><td style='width:54pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >245</td><td style='width:10.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' >$</td><td style='width:54pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >183</td></tr><tr style='height:15pt;' ><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:114pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:114pt;' ></td><td style='width:9.75pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:9.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:9.75pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:9.75pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td></tr><tr style='height:14.25pt;' ><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:114pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:114pt;' ></td><td style='width:9.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:9.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:9.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:9.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td></tr><tr style='height:14.25pt;' ><td colspan='10' rowspan='1' style='width:379.5pt;text-align:left;vertical-align:top;border-color:Black;min-width:379.5pt;' >The following table provides the components of and changes in the Company's restructuring accruals:</td></tr><tr style='height:33pt;' ><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:114pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:114pt;' > </td><td colspan='2' rowspan='1' style='width:63.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:63.75pt;' >Employee termination costs</td><td style='width:9.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td colspan='2' rowspan='1' style='width:63.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:63.75pt;' >Other</td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td colspan='2' rowspan='1' style='width:63.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:63.75pt;' >Total</td></tr><tr style='height:14.25pt;' ><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:114pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:114pt;' ></td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:9.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-top-style:solid;border-top-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td></tr><tr style='height:14.25pt;' ><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:114pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:114pt;' ></td><td colspan='8' rowspan='1' style='width:211.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:211.5pt;' >(U.S. $ in millions )</td></tr><tr style='height:14.25pt;' ><td colspan='2' rowspan='1' style='width:168pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:168pt;' >Balance as of January 1, 2016</td><td style='width:9.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' >$</td><td style='width:54pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >(105)</td><td style='width:9.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:9.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' >$</td><td style='width:54pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >(10)</td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:9.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' >$</td><td style='width:54pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >(115)</td></tr><tr style='height:14.25pt;' ><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:114pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:114pt;' >Provision</td><td style='width:9.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >(211)</td><td style='width:9.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:9.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >(34)</td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:9.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >(245)</td></tr><tr style='height:14.25pt;' ><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:114pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:114pt;' >Utilization and other* </td><td style='width:9.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >172</td><td style='width:9.75pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:9.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >35</td><td style='width:10.5pt;text-align:center;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:9.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >207</td></tr><tr style='height:15pt;' ><td colspan='2' rowspan='1' style='width:168pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:168pt;' >Balance as of December 31, 2016</td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' >$</td><td style='width:54pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >(144)</td><td style='width:9.75pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' >$</td><td style='width:54pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >(9)</td><td style='width:10.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' >$</td><td style='width:54pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >(153)</td></tr><tr style='height:15pt;' ><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:114pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:114pt;' >Provision</td><td style='width:9.75pt;border-top-style:double;border-top-width:3;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-top-style:double;border-top-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >(443)</td><td style='width:9.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:9.75pt;border-top-style:double;border-top-width:3;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-top-style:double;border-top-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >(92)</td><td style='width:10.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:9.75pt;border-top-style:double;border-top-width:3;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-top-style:double;border-top-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >(535)</td></tr><tr style='height:14.25pt;' ><td style='width:54pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td><td style='width:114pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:114pt;' >Utilization and other* </td><td style='width:9.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >293</td><td style='width:9.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:9.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >84</td><td style='width:10.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:9.75pt;border-bottom-style:solid;border-bottom-width:1;text-align:center;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:54pt;border-bottom-style:solid;border-bottom-width:1;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >377</td></tr><tr style='height:15pt;' ><td colspan='2' rowspan='1' style='width:168pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:168pt;' >Balance as of December 31, 2017</td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' >$</td><td style='width:54pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >(294)</td><td style='width:9.75pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' ></td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' >$</td><td style='width:54pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >(17)</td><td style='width:10.5pt;text-align:right;vertical-align:bottom;border-color:Black;min-width:10.5pt;' ></td><td style='width:9.75pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:9.75pt;' >$</td><td style='width:54pt;border-top-style:solid;border-top-width:1;border-bottom-style:double;border-bottom-width:3;text-align:right;vertical-align:bottom;border-color:Black;min-width:54pt;' >(311)</td></tr><tr style='height:15.75pt;' ><td colspan='9' rowspan='1' style='width:325.5pt;text-align:left;vertical-align:bottom;border-color:Black;min-width:325.5pt;' >* Includes adjustments for foreign currency translation.</td><td style='width:54pt;border-top-style:double;border-top-width:3;text-align:left;vertical-align:bottom;border-color:Black;min-width:54pt;' ></td></tr></table></div><div>On December 14, 2017, Teva’s President and CEO announced the launch of comprehensive two year restructuring plan (the "Plan") in order to restore the Company's financial security and stabilize its business. The Plan is intended to reduce Teva’s total cost base by $3 billion by the end of 2019, out of an estimated cost base of $16.1 billion in 2017. More than half of the reduction is expected to be achieved by the end of 2018. The company expects to record a restructuring charge as a result of the implementation of the Plan in 2018, mainly related to employee termination benefit costs, with additional charges possible following decisions on closures or divestments of manufacturing plants, R&D facilities, headquarters and other office locations. The Plan will focus on:• The immediate implementation of the new unified and simplified organizational structure, announced on November 27, 2017, which is intended to deliver cost savings and increase internal efficiencies.• Optimization of the global generics portfolio, specifically in the United States, through price adjustments and/or product discontinuations. Restructuring of the Company’s manufacturing and supply network, including the closures or divestments of a significant number of manufacturing plants in the United States, Europe, Israel and Growth Markets• Closures or divestments of a significant number of R&D facilities, headquarters and other office locations across all geographies.• A thorough review of all R&D programs in order to prioritize core projects while maintaining a substantial pipeline. These steps are expected to result in the reduction of 14,000 positions globally (approximately 25% of Teva’s total workforce as of December 31, 2017) by the end of 2019.</div><div>b. Share in profits or losses of associated companies–net:Share in profits or losses of associated companies – net, were a loss of $3 million in 2017, a gain of $8 million in 2016, and a loss of $121 million in 2015 respectively.</div>

CY2015

teva

Legal Settlements Acquisition And Restructuring And Impairment

LegalSettlementsAcquisitionAndRestructuringAndImpairment

631000000

USD

CY2016

teva

Legal Settlements Acquisition And Restructuring And Impairment

LegalSettlementsAcquisitionAndRestructuringAndImpairment

899000000

USD

CY2017

teva

Legal Settlements Acquisition And Restructuring And Impairment

LegalSettlementsAcquisitionAndRestructuringAndImpairment

500000000

USD

CY2016Q4

teva

Accrued Amount Legal Sttlement

AccruedAmountLegalSttlement

1500000000

USD

CY2017Q4

teva

Accrued Amount Legal Sttlement

AccruedAmountLegalSttlement

1200000000

USD

CY2016Q4

teva

Fcpa Settlements

FcpaSettlements

519000000

USD

CY2017

teva

Profitability Of Ms As Percentage Of Copaxone Revenues

ProfitabilityOfMsAsPercentageOfCopaxoneRevenues

80.6

pure

CY2015

teva

Profitability Of Ms As Percentage Of Copaxone Revenues

ProfitabilityOfMsAsPercentageOfCopaxoneRevenues

76.7

pure

CY2017

teva

Percentage Of Copaxone Revenues Of Total Non Us

PercentageOfCopaxoneRevenuesOfTotalNonUs

0

pure

CY2016

teva

Profitability Of Ms As Percentage Of Copaxone Revenues

ProfitabilityOfMsAsPercentageOfCopaxoneRevenues

81.3

pure

CY2017

us-gaap

Net Income Loss Available To Common Stockholders Diluted

NetIncomeLossAvailableToCommonStockholdersDiluted

-16525000000

USD

CY2016

us-gaap

Net Income Loss Available To Common Stockholders Diluted

NetIncomeLossAvailableToCommonStockholdersDiluted

68000000

USD

CY2015

us-gaap

Net Income Loss Available To Common Stockholders Diluted

NetIncomeLossAvailableToCommonStockholdersDiluted

1573000000

USD

CY2016

us-gaap

Incremental Common Shares Attributable To Share Based Payment Arrangements

IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

3000000

shares

CY2016

us-gaap

Incremental Common Shares Attributable To Conversion Of Debt Securities

IncrementalCommonSharesAttributableToConversionOfDebtSecurities

3000000

shares

CY2015

us-gaap

Incremental Common Shares Attributable To Share Based Payment Arrangements

IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

5000000

shares

CY2015

us-gaap

Incremental Common Shares Attributable To Conversion Of Debt Securities

IncrementalCommonSharesAttributableToConversionOfDebtSecurities

4000000

shares

CY2016Q4

teva

Weighted Average Of Mandatory Convertible Preferred Shares

WeightedAverageOfMandatoryConvertiblePreferredShares

59000000

shares

CY2016Q4

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

1123402689

shares

CY2017

dei

Document Type

DocumentType

10-K

CY2017

dei

Document Period End Date

DocumentPeriodEndDate

2017-12-31

CY2017

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2017

CY2017

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

Q4

CY2017

dei

Entity Registrant Name

EntityRegistrantName

TEVA PHARMACEUTICAL INDUSTRIES LTD

CY2017

dei

Entity Central Index Key

EntityCentralIndexKey

0000818686

CY2017

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

CY2017

dei

Amendment Flag

AmendmentFlag

false

CY2017

dei

Entity Voluntary Filers

EntityVoluntaryFilers

Yes

CY2017

dei

Entity Well Known Seasoned Issuer

EntityWellKnownSeasonedIssuer

Yes

CY2017

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

CY2017

dei

Trading Symbol

TradingSymbol

TEVA

CY2017

dei

Entity Filer Category

EntityFilerCategory

Large Accelerated Filer

CY2015

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

984000000

USD

CY2016Q4

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

7523000000

USD

CY2016Q4

us-gaap

Inventory Net

InventoryNet

4954000000

USD

CY2016Q4

teva

Prepaid Expenses

PrepaidExpenses

1629000000

USD

CY2016Q4

teva

Other Current Assets

OtherCurrentAssets

1293000000

USD

CY2016Q4

teva

Assets Held For Sale

AssetsHeldForSale

841000000

USD

CY2016Q4

us-gaap

Assets Current

AssetsCurrent

17228000000

USD

CY2016Q4

teva

Non Current Deferred Income Taxes

NonCurrentDeferredIncomeTaxes

625000000

USD

CY2016Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1235000000

USD

CY2016Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

8073000000

USD

CY2016Q4

us-gaap

Assets

93057000000

USD

CY2016Q4

us-gaap

Debt Current

DebtCurrent

3276000000

USD

CY2016Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

2157000000

USD

CY2016Q4

teva

Accrued Expenses

AccruedExpenses

3405000000

USD

CY2016Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

836000000

USD

CY2016Q4

teva

Liabilities Of Assets Held For Sales

LiabilitiesOfAssetsHeldForSales

116000000

USD

CY2016Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

18488000000

USD

CY2016Q4

us-gaap

Deferred Tax Liabilities Noncurrent

DeferredTaxLiabilitiesNoncurrent

5413000000

USD

CY2016Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1639000000

USD

CY2016Q4

us-gaap

Long Term Notes And Loans

LongTermNotesAndLoans

32524000000

USD

CY2016Q4

us-gaap

Liabilities Noncurrent

LiabilitiesNoncurrent

39576000000

USD

CY2016Q4

us-gaap

Liabilities

58064000000

USD

CY2016Q4

us-gaap

Preferred Stock Value

PreferredStockValue

3620000000

USD

CY2016Q4

us-gaap

Common Stock Value

CommonStockValue

54000000

USD

CY2016Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

13607000000

USD

CY2016Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-3159000000

USD

CY2016Q4

us-gaap

Treasury Stock Value

TreasuryStockValue

4194000000

USD

CY2016Q4

us-gaap

Stockholders Equity

StockholdersEquity

33337000000

USD

CY2016Q4

us-gaap

Minority Interest

MinorityInterest

1656000000

USD

CY2016Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

34993000000

USD

CY2016Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

93057000000

USD

CY2017Q4

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

7128000000

USD

CY2017Q4

us-gaap

Inventory Net

InventoryNet

4924000000

USD

CY2017Q4

teva

Assets Held For Sale

AssetsHeldForSale

566000000

USD

CY2017Q4

teva

Prepaid Expenses

PrepaidExpenses

1100000000

USD

CY2017Q4

teva

Other Current Assets

OtherCurrentAssets

701000000

USD

CY2017Q4

us-gaap

Assets Current

AssetsCurrent

15382000000

USD

CY2017Q4

teva

Non Current Deferred Income Taxes

NonCurrentDeferredIncomeTaxes

574000000

USD

CY2017Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

932000000

USD

CY2017Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

7673000000

USD

CY2017Q4

us-gaap

Assets

70615000000

USD

CY2017Q4

us-gaap

Debt Current

DebtCurrent

3646000000

USD

CY2017Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

2069000000

USD

CY2017Q4

teva

Accrued Expenses

AccruedExpenses

3014000000

USD

CY2017Q4

teva

Liabilities Of Assets Held For Sales

LiabilitiesOfAssetsHeldForSales

38000000

USD

CY2017Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

724000000

USD

CY2017Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

17921000000

USD

CY2017Q4

us-gaap

Deferred Tax Liabilities Noncurrent

DeferredTaxLiabilitiesNoncurrent

3277000000

USD

CY2017Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1843000000

USD

CY2017Q4

us-gaap

Long Term Notes And Loans

LongTermNotesAndLoans

28829000000

USD

CY2017Q4

us-gaap

Liabilities Noncurrent

LiabilitiesNoncurrent

33949000000

USD

CY2017Q4

us-gaap

Liabilities

51870000000

USD

CY2017Q4

us-gaap

Preferred Stock Value

PreferredStockValue

3631000000

USD

CY2017Q4

us-gaap

Common Stock Value

CommonStockValue

54000000

USD

CY2017Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-3803000000

USD

CY2017Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-1853000000

USD

CY2017Q4

us-gaap

Treasury Stock Value

TreasuryStockValue

4149000000

USD

CY2017Q4

us-gaap

Stockholders Equity

StockholdersEquity

17359000000

USD

CY2017Q4

us-gaap

Minority Interest

MinorityInterest

1386000000

USD

CY2017Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

18745000000

USD

CY2017Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

70615000000

USD

CY2016

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

955000000

shares

CY2017

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

1016000000

shares

CY2015

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

855000000

shares

CY2015Q4

us-gaap

Goodwill

19025000000

USD

CY2017

teva

Goodwill Impairment

GoodwillImpairment

-17100000000

USD

CY2016

teva

Goodwill Disposed

GoodwillDisposed

-99000000

USD

CY2017

teva

Goodwill Disposed

GoodwillDisposed

-697000000

USD

CY2017

teva

Goodwill Reclassification

GoodwillReclassification

-275000000

USD

CY2016

us-gaap

Goodwill Purchase Accounting Adjustments

GoodwillPurchaseAccountingAdjustments

26829000000

USD

CY2016Q4

teva

Returns

844000000

USD

CY2017Q4

us-gaap

Available For Sale Securities

AvailableForSaleSecurities

102000000

USD

CY2016

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

0

USD

CY2015

us-gaap

Sales Revenue Net

SalesRevenueNet

19652000000

USD

CY2016

us-gaap

Sales Revenue Net

SalesRevenueNet

21903000000

USD

CY2017

us-gaap

Sales Revenue Net

SalesRevenueNet

22385000000

USD

CY2016

us-gaap

Profit Loss

ProfitLoss

311000000

USD

CY2017

us-gaap

Profit Loss

ProfitLoss

-16449000000

USD

CY2017Q4

teva

Returns

780000000

USD

CY2017Q4

us-gaap

Deferred Tax Assets Liabilities Net

DeferredTaxAssetsLiabilitiesNet

-2703000000

USD

CY2016

teva

Business Combination Consideration Transferred Equity Based Compensation

BusinessCombinationConsiderationTransferredEquityBasedCompensation

25000000

USD

CY2016

teva

Business Combination Consideration Transferred Contingent Consideration

BusinessCombinationConsiderationTransferredContingentConsideration

302000000

USD

CY2016

us-gaap

Business Combination Consideration Transferred1

BusinessCombinationConsiderationTransferred1

39270000000

USD

CY2017Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

-717000000

USD

CY2016Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

-811000000

USD

CY2015Q4

us-gaap

Restructuring Reserve

RestructuringReserve

-115000000

USD

CY2016Q4

us-gaap

Restructuring Reserve

RestructuringReserve

-153000000

USD

CY2017Q4

us-gaap

Restructuring Reserve

RestructuringReserve

-311000000

USD

CY2016

teva

Utilization And Other

UtilizationAndOther

207000000

USD

CY2017

teva

Utilization And Other

UtilizationAndOther

377000000

USD

CY2015

us-gaap

Increase Decrease In Operating Capital

IncreaseDecreaseInOperatingCapital

-967000000

USD

CY2015

us-gaap

Asset Impairment Charges

AssetImpairmentCharges

361000000

USD

CY2016

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

1524000000

USD

CY2017

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

-18379000000

USD

CY2015Q4

teva

Mandatoryconvertible Preferred Shares Issued During Period Shares New Issues

MandatoryconvertiblePreferredSharesIssuedDuringPeriodSharesNewIssues

3291000000

USD

CY2015

teva

Profit From Sale Of Long Lived Assets And Investment

ProfitFromSaleOfLongLivedAssetsAndInvestment

86000000

USD

CY2015

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

35000000

USD

CY2015

teva

Gain From Revaluation Of Investments

GainFromRevaluationOfInvestments

-736000000

USD

CY2015

us-gaap

Share Based Compensation

ShareBasedCompensation

117000000

USD

CY2015

teva

Deferred Income Taxes Net And Uncertain Tax Positions

DeferredIncomeTaxesNetAndUncertainTaxPositions

237000000

USD

CY2015

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-146000000

USD

CY2017

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

2112000000

USD

CY2015

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

1308000000

USD

CY2015

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

5542000000

USD

CY2015

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

3309000000

USD

CY2015

us-gaap

Proceeds From Sale And Maturity Of Marketable Securities

ProceedsFromSaleAndMaturityOfMarketableSecurities

524000000

USD

CY2015

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

772000000

USD

CY2015

teva

Payment To Aquire Marketable Securities And Other Assets

PaymentToAquireMarketableSecuritiesAndOtherAssets

2003000000

USD

CY2015

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

5000000

USD

CY2015

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-5565000000

USD

CY2015

teva

Proceeds From Long Term Loans And Other Long Term Liabilities

ProceedsFromLongTermLoansAndOtherLongTermLiabilities

2099000000

USD

CY2015

us-gaap

Proceeds From Repayments Of Short Term Debt

ProceedsFromRepaymentsOfShortTermDebt

29000000

USD

CY2015

us-gaap

Payments Of Dividends Common Stock

PaymentsOfDividendsCommonStock

1155000000

USD

CY2015

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

2521000000

USD

CY2015

teva

Payments Of Dividends Preferred Stock

PaymentsOfDividendsPreferredStock

0

USD

CY2015

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

-178000000

USD

CY2015

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

388000000

USD

CY2015

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

4805000000

USD

CY2015

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

-62000000

USD

CY2014Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

2226000000

USD

CY2015Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

6946000000

USD

CY2015

us-gaap

Cash And Cash Equivalents Period Increase Decrease

CashAndCashEquivalentsPeriodIncreaseDecrease

4720000000

USD

CY2016Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

988000000

USD

CY2017Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

963000000

USD

CY2016Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

21487000000

USD

CY2017Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

17640000000

USD

CY2016Q4

us-gaap

Goodwill

44409000000

USD

CY2017Q4

us-gaap

Goodwill

28414000000

USD

CY2016Q4

teva

Sales Reserves And Allowances

SalesReservesAndAllowances

7839000000

USD

CY2017Q4

teva

Sales Reserves And Allowances

SalesReservesAndAllowances

7881000000

USD

CY2015

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

1360000000

USD

CY2016

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

1285000000

USD

CY2017

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

1330000000

USD

CY2015

teva

Impairments Restructuring And Others

ImpairmentsRestructuringAndOthers

1176000000

USD

CY2016

teva

Impairments Restructuring And Others

ImpairmentsRestructuringAndOthers

1419000000

USD

CY2017

teva

Impairments Restructuring And Others

ImpairmentsRestructuringAndOthers

5074000000

USD

CY2015

teva

Legal Settlements And Loss Contingencies

LegalSettlementsAndLossContingencies

631000000

USD

CY2016

teva

Legal Settlements And Loss Contingencies

LegalSettlementsAndLossContingencies

899000000

USD

CY2017

teva

Legal Settlements And Loss Contingencies

LegalSettlementsAndLossContingencies

500000000

USD

CY2015

us-gaap

Operating Income Loss

OperatingIncomeLoss

3352000000

USD

CY2016

us-gaap

Operating Income Loss

OperatingIncomeLoss

2154000000

USD

CY2017

us-gaap

Operating Income Loss

OperatingIncomeLoss

-17484000000

USD

CY2015

us-gaap

Nonoperating Income Expense

NonoperatingIncomeExpense

-1000000000

USD

CY2016

us-gaap

Nonoperating Income Expense

NonoperatingIncomeExpense

-1330000000

USD

CY2017

us-gaap

Nonoperating Income Expense

NonoperatingIncomeExpense

-895000000

USD

CY2015

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

2352000000

USD

CY2016

us-gaap

Proceeds From Issuance Of Preferred Stock And Preference Stock

ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

329000000

USD

CY2016

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

824000000

USD

CY2016

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

329000000

USD

CY2015

us-gaap

Dividends Common Stock Cash

DividendsCommonStockCash

1155000000

USD

CY2015

us-gaap

Stock Issued During Period Value Treasury Stock Reissued

StockIssuedDuringPeriodValueTreasuryStockReissued

439000000

USD

CY2015

us-gaap

Impairment Of Investments

ImpairmentOfInvestments

124000000

USD

CY2016

us-gaap

Impairment Of Investments

ImpairmentOfInvestments

0

USD

CY2015

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

3291000000

USD

CY2015

us-gaap

Proceeds From Issuance Of Preferred Stock And Preference Stock

ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

3291000000

USD

CY2017

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

0

USD

CY2017

us-gaap

Proceeds From Issuance Of Preferred Stock And Preference Stock

ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

0

USD

CY2017

teva

Payments Of Dividends To Non Controlling Interest

PaymentsOfDividendsToNonControllingInterest

38000000

USD

CY2016

teva

Payments Of Dividends To Non Controlling Interest

PaymentsOfDividendsToNonControllingInterest

0

USD

CY2015

teva

Payments Of Dividends To Non Controlling Interest

PaymentsOfDividendsToNonControllingInterest

0

USD

CY2016

us-gaap

Business Combination Consideration Transferred Equity Interests Issued And Issuable

BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable

5065000000

USD

CY2017Q4

teva

Availableforsalesecuritiesdebtmaturitiesyearthreefairvalue

18000000

USD

CY2017

us-gaap

Incremental Common Shares Attributable To Share Based Payment Arrangements

IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

0

shares

CY2017

us-gaap

Incremental Common Shares Attributable To Conversion Of Debt Securities

IncrementalCommonSharesAttributableToConversionOfDebtSecurities

0

shares

CY2016Q4

teva

Revolving Credit Facility

RevolvingCreditFacility

1240000000

USD

CY2016Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

15000000

USD

CY2017Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

1000000

USD

CY2017Q4

teva

Revolving Credit Facility

RevolvingCreditFacility

0

USD

CY2016Q4

teva

Termloan Jpy2

TermloanJPY2

0

USD

CY2017Q4

teva

Termloan Jpy2

TermloanJPY2

251000000

USD

CY2015

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

439000000

USD

CY2017

us-gaap

Income Tax Reconciliation Tax Contingencies

IncomeTaxReconciliationTaxContingencies

-25000000

USD

CY2017

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

0

USD

CY2016

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

0

USD

CY2015

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

0

USD

CY2016Q4

teva

Inventory Related

InventoryRelated

-46000000

USD

CY2016Q4

teva

Sales Reserves And Allowance

SalesReservesAndAllowance

-311000000

USD

CY2016Q4

teva

Provision For Legal Settlements

ProvisionForLegalSettlements

-232000000

USD

CY2017

us-gaap

Restructuring Charges

RestructuringCharges

535000000

USD

CY2017

us-gaap

Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1

BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

154000000

USD

CY2017

teva

Venezuela Deconsolidation Charge

VenezuelaDeconsolidationCharge

396000000

USD

CY2016

teva

Venezuela Deconsolidation Charge

VenezuelaDeconsolidationCharge

0

USD

CY2015

teva

Venezuela Deconsolidation Charge

VenezuelaDeconsolidationCharge

0

USD

CY2015

us-gaap

Dividends Preferred Stock Cash

DividendsPreferredStockCash

-15000000

USD

CY2017

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

-1933000000

USD

CY2017

teva

Inventory Step Up

InventoryStepUp

67000000

USD

CY2016

teva

Inventory Step Up

InventoryStepUp

381000000

USD

CY2015

teva

Inventory Step Up

InventoryStepUp

0

USD

CY2016

teva

Venezuela Impairment Of Net Monetary Assets

VenezuelaImpairmentOfNetMonetaryAssets

603000000

USD

CY2017

teva

Legal Textblock

LegalTextblock

<div>NOTE 19—LEGAL SETTLEMENTS AND LOSS CONTINGENCIES:Legal settlements and loss contingencies for 2017 amounted to $500 million, compared to $899 million and $631 million in 2016 and 2015, respectively. The 2017 expense primarily consisted of reserve for the carvedilol jury trial loss established in Q2 2017. The expenses in 2016 primarily consisted of a $519 million provision established in connection with the FCPA settlement with the DOJ and SEC and a $225 million provision established in connection with the ciprofloxacin settlement. As of December 31, 2017 and 2016, accrued amounts for legal settlements and loss contingencies of $1.2 billion and $1.5 billion, respectively, are recorded in accrued expenses.</div>

CY2017

us-gaap

Concentration Risk Credit Risk

ConcentrationRiskCreditRisk

<div>j. Concentration of credit risks: Most of Teva’s cash and cash equivalents (which, along with investment in securities, totaled $1.1 billion at December 31, 2017) were deposited with financially sound European, U.S. and Israeli banks and financial institutions and were comprised mainly of cash deposits. The pharmaceutical industry, particularly in the United States., has been significantly affected by consolidation among managed care providers, large pharmacy chains, wholesaling organizations and other buyer groups. The U.S. market constituted approximately 53% of Teva's consolidated revenues in 2017. The exposure of credit risks relating to other trade receivables is limited, due to the relatively large number of group customers and their wide geographic distribution. Teva performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts and generally does not require collateral. An appropriate allowance for doubtful accounts is included in the accounts and netted against trade receivables.</div>

CY2017

us-gaap

Prior Period Reclassification Adjustment Description

PriorPeriodReclassificationAdjustmentDescription

<div>bb. Reclassifications: Certain comparative figures have been reclassified to conform to the current year presentation</div>

CY2017

teva

Other Revenue

OtherRevenue

394000000

USD

teva

Iprdtoproductrights

1700000000

USD

teva

Iprdtoproductrights

1300000000

USD

CY2017Q4

teva

Long Term Investments Earmarked For Domestic Severance Obligations

LongTermInvestmentsEarmarkedForDomesticSeveranceObligations

149000000

USD

CY2017Q4

teva

Interest Rate Swap Gain

InterestRateSwapGain

7000000

USD

CY2017

teva

Gain From Currency Swap

GainFromCurrencySwap

13000000

USD

CY2017

teva

Deferred Purchase Asset

DeferredPurchaseAsset

261000000

USD

CY2016

teva

Deferred Purchase Asset

DeferredPurchaseAsset

220000000

USD

CY2017

teva

Restructuring Plan Cost Reduction

RestructuringPlanCostReduction

3000000000

USD

CY2017

teva

Estimated Base Costs And Expenses

EstimatedBaseCostsAndExpenses

16100000000

USD

CY2017

teva

Positions Reduction

PositionsReduction

14000

CY2017Q4

teva

Term Loan Jpy55 Libor Plus

TermLoanJpy55LiborPlus

JPY LIBOR +0.55%

CY2016Q4

teva

Utp Due To No Ls St

UTPDueToNOLsST

23000000

USD

CY2017Q4

teva

Utp Due To No Ls St

UTPDueToNOLsST

26000000

USD

CY2017Q4

teva

Japanese Business Venture Minority Interest

JapaneseBusinessVentureMinorityInterest

1600000000

USD

CY2017Q4

teva

Fda Priority Review Voucher

FdaPriorityReviewVoucher

150000000

USD

CY2016Q4

teva

Debt Issuance And Term Loan Facilities Related

DebtIssuanceAndTermLoanFacilitiesRelated

100000000

USD

CY2018Q1

teva

Allergan One Time Payment To Teva

AllerganOneTimePaymentToTeva

700000000

USD

CY2015

teva

Proceeds From Issuance Or Sale Of Equity Ads

ProceedsFromIssuanceOrSaleOfEquityAds

3300000000

USD

CY2015

teva

Proceeds From Issuance Or Sale Of Equity Convertible Preferred Shares

ProceedsFromIssuanceOrSaleOfEquityConvertiblePreferredShares

3300000000

USD

CY2017Q4

teva

Dividend Declared Mandatory Convertible Preferred Shares

DividendDeclaredMandatoryConvertiblePreferredShares

17500000

USD

CY2017Q4

teva

Foreign Currency Translation Attributable To Noncontrolling Interests

ForeignCurrencyTranslationAttributableToNoncontrollingInterests

63000000

USD

CY2017Q4

us-gaap

Share Price

SharePrice

18.95

CY2017Q4

teva

Average Share Price

AverageSharePrice

25.62

CY2015Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

29927000000

USD

CY2016Q4

teva

Shares Issued To Purchase Actavis Generics

SharesIssuedToPurchaseActavisGenerics

5065000000

USD

CY2015Q4

teva

Shares Issued To Purchase Actavis Generics

SharesIssuedToPurchaseActavisGenerics

0

USD

CY2016Q4

teva

Shares Transferred To Takeda

SharesTransferredToTakeda

1825000000

USD

CY2015Q4

teva

Shares Transferred To Takeda

SharesTransferredToTakeda

0

USD

CY2016Q4

teva

Actavis Contingent Consideration

ActavisContingentConsideration

302000000

USD

CY2017Q4

us-gaap

Operating Leases Future Minimum Payments Due In Two Years

OperatingLeasesFutureMinimumPaymentsDueInTwoYears

132000000

USD

CY2017Q4

us-gaap

Operating Leases Future Minimum Payments Due Thereafter

OperatingLeasesFutureMinimumPaymentsDueThereafter

75000000

USD

CY2017Q4

teva

Ciprofloxacin Settlement

CiprofloxacinSettlement

225000000

USD

CY2017Q4

teva

Cinqair Plaintiffs Claim Damages

CinqairPlaintiffsClaimDamages

200000000

USD

CY2017Q4

teva

Milestones Payable To The Former Shareholders Of Ception Us

MilestonesPayableToTheFormerShareholdersOfCeptionUs

150000000

USD

CY2017Q4

teva

Milestones Payable To The Former Shareholders Of Ception Eur

MilestonesPayableToTheFormerShareholdersOfCeptionEur

50000000

USD

CY2018Q1

teva

Arrangement For The Contingent Cessation Of Proceedings Pursuant To The Israeli Securities Law

ArrangementForTheContingentCessationOfProceedingsPursuantToTheIsraeliSecuritiesLaw

75000000

ILS

CY2018Q1

teva

Arrangement For The Contingent Cessation Of Proceedings Pursuant To The Israeli Securities Law

ArrangementForTheContingentCessationOfProceedingsPursuantToTheIsraeliSecuritiesLaw

22000000

USD

CY2011Q4

teva

Modafinileurosales

46500000

EUR

CY2014Q4

teva

Annual Sale Of Velcade

AnnualSaleOfVelcade

94000000

CAD

CY2017Q4

teva

Max Damages Payable With Janssen And Millenium

MaxDamagesPayableWithJanssenAndMillenium

200000000

CAD

CY2017Q4

teva

Milestone Contingent Payments

MilestoneContingentPayments

407000000

USD

CY2017

teva

Plan B Sale Agreement

PlanBSaleAgreement

675000000

USD

CY2017

teva

Cost Of Sale Of Business

CostOfSaleOfBusiness

15000000

USD

CY2017Q4

us-gaap

Accounts Receivable From Securitization

AccountsReceivableFromSecuritization

799000000

USD

CY2017Q4

us-gaap

Senior Notes

SeniorNotes

28367000000

USD

CY2017Q4

us-gaap

Notes Payable

NotesPayable

3426000000

USD

CY2017Q4

teva

Long Term Debentures

LongTermDebentures

20000000

USD

CY2017Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Next Twelve Months

LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

-2880000000

USD

CY2017Q4

teva

Longtermderivativeinstruments

2000000

USD

CY2018Q1

teva

Line Of Credit Facility

LineOfCreditFacility

3000000000

USD

CY2017Q4

teva

Long Term Debt Currency Portion Usd

LongTermDebtCurrencyPortionUSD

64

pure

CY2017Q4

teva

Long Term Debt Currency Portion Eur

LongTermDebtCurrencyPortionEUR

31

pure

CY2017Q4

teva

Long Term Debt Currency Portion Chf

LongTermDebtCurrencyPortionCHF

2

pure

CY2017Q4

teva

Long Term Debt Currency Portion Jpy

LongTermDebtCurrencyPortionJPY

3

pure

CY2017Q4

teva

Syndicate Of Banks Loan

SyndicateOfBanksLoan

86800000000

JPY

CY2017Q4

teva

Syndicate Of Banks Loan5 Years

SyndicateOfBanksLoan5Years

58500000000

JPY

CY2017Q4

teva

Syndicate Of Banks Loan1 Year

SyndicateOfBanksLoan1Year

28300000000

JPY

CY2017

us-gaap

Royalty Expense

RoyaltyExpense

956000000

USD

CY2016

us-gaap

Royalty Expense

RoyaltyExpense

814000000

USD

CY2015

us-gaap

Royalty Expense

RoyaltyExpense

911000000

USD

CY2017Q4

us-gaap

Long Term Debt

LongTermDebt

28829000000

USD

CY2017Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

19129000

shares

CY2017Q4

teva

Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price2010

ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010

47.94

CY2017Q4

teva

Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2010

ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010

5.57

USD

CY2017Q4

us-gaap

Shares Outstanding

SharesOutstanding

1100000000

shares

CY2016Q4

teva

Shareincrease

33300000

shares

CY2017Q4

teva

Equivalent Share Units Forfuture Grants

EquivalentShareUnitsForfutureGrants

99400000

shares

CY2017Q4

teva

Equivalent Share Units Approval For Grant

EquivalentShareUnitsApprovalForGrant

65000000

shares

CY2015Q4

us-gaap

Convertible Preferred Stock Shares Issued Upon Conversion

ConvertiblePreferredStockSharesIssuedUponConversion

3375000

shares

CY2016Q1

teva

Adss Offering

AdssOffering

5400000

shares

CY2016Q1

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

0.85

CY2016

teva

Transactions Termination Loss Settled

TransactionsTerminationLossSettled

242000000

USD

CY2017

teva

Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses

ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses

27000000

USD

CY2016

teva

Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses

ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses

12000000

USD

CY2017

teva

Reclassification To Investment Activities

ReclassificationToInvestmentActivities

1300000000

USD

CY2017Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

23479000000

USD

CY2016Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

23409000000

USD

CY2015

us-gaap

Preferred Stock Dividends Income Statement Impact

PreferredStockDividendsIncomeStatementImpact

15000000

USD

CY2016

us-gaap

Preferred Stock Dividends Income Statement Impact

PreferredStockDividendsIncomeStatementImpact

261000000

USD

CY2017

us-gaap

Preferred Stock Dividends Income Statement Impact

PreferredStockDividendsIncomeStatementImpact

260000000

USD

CY2015

teva

Gains On Divestitures

GainsOnDivestitures

45000000

USD

CY2015

teva

Gain On Litigation Settlements

GainOnLitigationSettlements

25000000

USD

CY2015

teva

Gain On Sale Of Assets

GainOnSaleOfAssets

44000000

USD

CY2015

teva

Other Income Net

OtherIncomeNet

52000000

USD

CY2016

teva

Gains On Divestitures

GainsOnDivestitures

720000000

USD

CY2016

teva

Gain On Litigation Settlements

GainOnLitigationSettlements

20000000

USD

CY2016

teva

Gain On Sale Of Assets

GainOnSaleOfAssets

10000000

USD

CY2016

teva

Other Income Net

OtherIncomeNet

19000000

USD

CY2017

teva

Gains On Divestitures

GainsOnDivestitures

1083000000

USD

CY2017

teva

Gain On Litigation Settlements

GainOnLitigationSettlements

83000000

USD

CY2017

teva

Gain On Sale Of Assets

GainOnSaleOfAssets

11000000

USD

CY2017

teva

Other Income Net

OtherIncomeNet

22000000

USD

CY2016Q4

teva

Debt Issuance Costs1

DebtIssuanceCosts1

-115000000

USD

CY2017Q4

teva

Debt Issuance Costs1

DebtIssuanceCosts1

-106000000

USD

CY2016Q4

us-gaap

Debt Instrument Carrying Amount

DebtInstrumentCarryingAmount

514000000

USD

CY2017Q4

us-gaap

Debt Instrument Carrying Amount

DebtInstrumentCarryingAmount

514000000

USD

CY2017Q1

us-gaap

Sales Revenue Net

SalesRevenueNet

5650000000

USD

CY2017Q1

us-gaap

Gross Profit

GrossProfit

2839000000

USD

CY2017Q2

us-gaap

Sales Revenue Net

SalesRevenueNet

5720000000

USD

CY2017Q2

us-gaap

Gross Profit

GrossProfit

2855000000

USD

CY2017Q3

us-gaap

Sales Revenue Net

SalesRevenueNet

5611000000

USD

CY2017Q3

us-gaap

Gross Profit

GrossProfit

2644000000

USD

CY2017Q4

us-gaap

Sales Revenue Net

SalesRevenueNet

5459000000

USD

CY2017Q4

us-gaap

Gross Profit

GrossProfit

2542000000

USD

CY2017Q1

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

0.57

CY2017Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-5.94

CY2017Q2

us-gaap

Goodwill Impairment Loss

GoodwillImpairmentLoss

6100000000

USD

CY2017Q4

us-gaap

Goodwill Impairment Loss

GoodwillImpairmentLoss

11000000000

USD

CY2017Q3

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

0.52

CY2016Q1

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

0.62

CY2016Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

0.21

CY2016Q3

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

0.35

CY2016Q4

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-1.02

CY2016Q1

us-gaap

Sales Revenue Net

SalesRevenueNet

4810000000

USD

CY2016Q1

us-gaap

Gross Profit

GrossProfit

2791000000

USD

CY2016Q2

us-gaap

Sales Revenue Net

SalesRevenueNet

5038000000

USD

CY2016Q2

us-gaap

Gross Profit

GrossProfit

2877000000

USD

CY2016Q3

us-gaap

Sales Revenue Net

SalesRevenueNet

5563000000

USD

CY2016Q3

us-gaap

Gross Profit

GrossProfit

2801000000

USD

CY2016Q4

us-gaap

Sales Revenue Net

SalesRevenueNet

6492000000

USD

CY2016Q4

us-gaap

Gross Profit

GrossProfit

3390000000

USD

CY2017

us-gaap

Increase Decrease In Operating Capital

IncreaseDecreaseInOperatingCapital

363000000

USD

CY2017Q4

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-11.41

CY2017Q4

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-11.41

CY2017Q3

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

0.52

CY2017Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-5.94

CY2017Q1

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

0.57

CY2016Q4

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-1.02

CY2016Q3

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

0.35

CY2016Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

0.2

CY2016Q1

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

0.62

CY2017Q4

teva

Net Income Loss Qtd

NetIncomeLossQtd

-11535000000

USD

CY2017Q3

teva

Net Income Loss Qtd

NetIncomeLossQtd

595000000

USD

CY2017Q2

teva

Net Income Loss Qtd

NetIncomeLossQtd

-5970000000

USD

CY2017Q1

teva

Net Income Loss Qtd

NetIncomeLossQtd

645000000

USD

CY2016Q4

teva

Net Income Loss Qtd

NetIncomeLossQtd

-973000000

USD

CY2016Q3

teva

Net Income Loss Qtd

NetIncomeLossQtd

412000000

USD

CY2016Q2

teva

Net Income Loss Qtd

NetIncomeLossQtd

254000000

USD

CY2016Q1

teva

Net Income Loss Qtd

NetIncomeLossQtd

636000000

USD

CY2017Q1

teva

Profit Loss Qtd

ProfitLossQtd

641000000

USD

CY2017Q2

teva

Profit Loss Qtd

ProfitLossQtd

-5970000000

USD

CY2017Q3

teva

Profit Loss Qtd

ProfitLossQtd

610000000

USD

CY2017Q4

teva

Profit Loss Qtd

ProfitLossQtd

-11730000000

USD

CY2016Q4

teva

Profit Loss Qtd

ProfitLossQtd

-974000000

USD

CY2016Q3

teva

Profit Loss Qtd

ProfitLossQtd

410000000

USD

CY2016Q2

teva

Profit Loss Qtd

ProfitLossQtd

242000000

USD

CY2016Q1

teva

Profit Loss Qtd

ProfitLossQtd

633000000

USD

CY2016

teva

Application Of Guidance On Deferred Income Tax Liabilities

ApplicationOfGuidanceOnDeferredIncomeTaxLiabilities

198000000

USD

CY2016

teva

Application Of Guidance On Deferred Income Tax Assets

ApplicationOfGuidanceOnDeferredIncomeTaxAssets

-100000000

USD

CY2016

teva

Application Of Guidance On Accrued Expenses Decreased

ApplicationOfGuidanceOnAccruedExpensesDecreased

31000000

USD

CY2017Q4

teva

Application Of Intra Entity Transfers Deferred Taxes

ApplicationOfIntraEntityTransfersDeferredTaxes

31000000

USD

CY2016

teva

Application Of Guidance On Prepaid Expenses

ApplicationOfGuidanceOnPrepaidExpenses

267000000

USD

CY2017Q4

teva

Long Term Debta Exclude Issuance Cost

LongTermDebtaExcludeIssuanceCost

28935000000

USD

CY2017Q4

teva

Debt Subject To Covenants

DebtSubjectToCovenants

3700000000

USD

CY2016

us-gaap

Tangible Asset Impairment Charges

TangibleAssetImpairmentCharges

149000000

USD

CY2015

us-gaap

Tangible Asset Impairment Charges

TangibleAssetImpairmentCharges

96000000

USD

CY2015

us-gaap

Impairment Of Intangible Assets Excluding Goodwill

ImpairmentOfIntangibleAssetsExcludingGoodwill

265000000

USD

CY2016

us-gaap

Impairment Of Intangible Assets Excluding Goodwill

ImpairmentOfIntangibleAssetsExcludingGoodwill

589000000

USD

CY2017

us-gaap

Impairment Of Intangible Assets Excluding Goodwill

ImpairmentOfIntangibleAssetsExcludingGoodwill

3238000000

USD

CY2016Q4

teva

Employee Related Obligations

EmployeeRelatedObligations

859000000

USD

CY2017Q4

teva

Employee Related Obligations

EmployeeRelatedObligations

549000000

USD

CY2016

teva

Cash To Acquire Businesses Acquisition

CashToAcquireBusinessesAcquisition

33878000000

USD

CY2015

us-gaap

Other Income

OtherIncome

166000000

USD

CY2016

us-gaap

Other Income

OtherIncome

769000000

USD

CY2016

teva

Investment In Debt Securities

InvestmentInDebtSecurities

16000000

USD

CY2016

teva

Foreincurrencytranslationdifferences

18000000

USD

CY2017

teva

Investment In Debt Securities

InvestmentInDebtSecurities

0

USD

CY2017

teva

Foreincurrencytranslationdifferences

-17000000

USD

CY2016

us-gaap

Goodwill Impairment Loss

GoodwillImpairmentLoss

900000000

USD

CY2017

us-gaap

Goodwill Impairment Loss

GoodwillImpairmentLoss

17100000000

USD

CY2017

us-gaap

Other Income

OtherIncome

1199000000

USD

CY2015

us-gaap

Profit Loss

ProfitLoss

1597000000

USD

CY2016Q4

teva

Venezuela Inventory Balance Adjustments

venezuelaInventoryBalanceAdjustments

133000000

USD

CY2016Q4

teva

Venezuela Devaluation Charge2

VenezuelaDevaluationCharge2

500000000

USD

CY2016Q4

teva

Venezuela Devaluation Charge

VenezuelaDevaluationCharge

246000000

USD

CY2017Q4

teva

Loan Payment Prepaid1

LoanPaymentPrepaid1

250000000

USD

CY2017Q4

teva

Loan Payment Prepaid2

LoanPaymentPrepaid2

170000000

USD

CY2017Q4

teva

Loan Payment Repaid

LoanPaymentRepaid

80000000

USD

CY2017

teva

Weighted Average Number Of Shares Outstanding Diluted

WeightedAverageNumberOfSharesOutstandingDiluted

1016000000

shares

CY2016

teva

Weighted Average Number Of Shares Outstanding Diluted

WeightedAverageNumberOfSharesOutstandingDiluted

961000000

shares

CY2015

teva

Weighted Average Number Of Shares Outstanding Diluted

WeightedAverageNumberOfSharesOutstandingDiluted

864000000

shares

CY2017

teva

Goodwill Impairment Loss Us Distribution

GoodwillImpairmentLossUsDistribution

560000000

USD

CY2017Q2

teva

Discounted Rate Us Generic

DiscountedRateUsGeneric

6.8

pure

CY2017Q2

teva

Assumed Terminal Growth Rate

AssumedTerminalGrowthRate

2

pure

CY2017

teva

Deconsolidation Loss

DeconsolidationLoss

383000000

USD

CY2016

teva

Deconsolidation Loss

DeconsolidationLoss

0

USD

CY2015

teva

Deconsolidation Loss

DeconsolidationLoss

0

USD

CY2015Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-1955000000

USD

CY2014Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-1343000000

USD

CY2017Q4

teva

Dividend Mandatory Convertible Preferred Shares

DividendMandatoryConvertiblePreferredShares

70

CY2011Q4

us-gaap

Stock Repurchase Program Authorized Amount1

StockRepurchaseProgramAuthorizedAmount1

1300000000

USD

CY2017Q4

us-gaap

Stock Repurchase Program Authorized Amount1

StockRepurchaseProgramAuthorizedAmount1

2100000000

USD

CY2014Q4

us-gaap

Stock Repurchase Program Authorized Amount1

StockRepurchaseProgramAuthorizedAmount1

1700000000

USD

CY2011

teva

Stock Repurchase Program Authorized Amount2

StockRepurchaseProgramAuthorizedAmount2

3000000000

USD

CY2017

teva

Tax Benefit Related To Tax Cuts And Jobs Act

TaxBenefitRelatedToTaxCutsAndJobsAct

1200000000

USD

CY2017

teva

Foreign Subsidiaries Tax Expense Related To Tax Cuts And Jobs Act

ForeignSubsidiariesTaxExpenseRelatedToTaxCutsAndJobsAct

112000000

USD

CY2017

teva

Ustaxcutsandjobsacteffect

1061000000

USD

CY2017Q4

teva

Asset Impairment Chargeslonglived Assets

AssetImpairmentChargeslonglivedAssets

3800000000

USD

CY2017Q4

teva

Contingent Consideration2

ContingentConsideration2

40000000

USD

CY2017

teva

Projections Assumptions Us Generics

ProjectionsAssumptionsUsGenerics

If Teva holds all other assumptions constant, a reduction in the terminal value growth rate by 0.1% or an increase in discount rate by 0.1% would each result in an additional impairment of approximately $190 million and $230 million, respectively.

CY2017

teva

Projections Assumptions Other Generics

ProjectionsAssumptionsOtherGenerics

Teva concluded that the fair value of each of its remaining reporting units within its generics medicines segment continues to be in excess of its carrying value. The remaining goodwill allocated to these reporting units was approximately $13.4 billion as of December 31, 2017. For these reporting units, the percentage excess of estimated fair value over carrying value, as of December 31, 2017, was 45.6% for Teva's Rimsa reporting unit, 4.6% for the European generics reporting unit and 4.1% for the ROW generics reporting unit.

CY2017

teva

Projections Assumptions Row Generics

ProjectionsAssumptionsRowGenerics

The resulting cash flow amounts for European generics reporting unit were discounted using a rate of 8.4% reflecting market participants' assumptions regarding increased uncertainties and country-specific characteristics with a terminal growth rate of 1.8%. If Teva holds all other assumptions constant, a reduction in the terminal value growth rate by 0.5% or an increase in discount rate by 0.4% would each result in impairment. The goodwill allocated to this reporting unit was $8.2 billion as of December 31, 2017.

CY2017

teva

Projections Assumptions Europe Generics

ProjectionsAssumptionsEuropeGenerics

The resulting cash flow amounts for ROW generics reporting unit were discounted using a rate of 8.8% reflecting market participants' assumptions regarding increased uncertainties and country-specific characteristics with a terminal growth rate of 3.5%. If Teva holds all other assumptions constant, a reduction in the terminal value growth rate by 0.3% or an increase in discount rate by 0.2% would each result in impairment. The goodwill allocated to this reporting unit was $4.3 billion as of December 31, 2017.

CY2017

teva

Projections Assumptions Specialty

ProjectionsAssumptionsSpecialty

Teva adjusted its projections for its specialty reporting unit to reflect significant events that took place during 2017, mainly the FDA approval of a generic version of COPAXONE and the subsequent launch at risk of a competing product in the U.S. market, as well as the unfavorable clinical trial result for laquinimod and the favorable clinical trial results for AUSTEDO and fremanezumab. Teva reflected the expected implications of these developments in the cash flow projections and discounted the adjusted cash flow amounts by adding an additional risk premium of 2.3% to the discount rate of 7.3%, which Teva uses for most of its worldwide operations, applying a market participant view, to reflect the increased uncertainties in its specialty business.

CY2017Q4

teva

Discounted Rate Us Generic

DiscountedRateUsGeneric

7.3

pure

CY2017Q4

teva

Goodwill Impairment Loss Us Generics

GoodwillImpairmentLossUsGenerics

10400000000

USD

CY2017

teva

Goodwill Impairment Loss Us Generics

GoodwillImpairmentLossUsGenerics

16500000000

USD

CY2015

us-gaap

Stock Issued During Period Shares New Issues

StockIssuedDuringPeriodSharesNewIssues

3291000000

shares

CY2017

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

3.7

pure

CY2017

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

29

pure

CY2017

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

2.1

pure

CY2016

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

2.6

pure

CY2016

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

25

pure

CY2016

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

1.4

pure

CY2015

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

2.3

pure

CY2015

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

24

pure

CY2015

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

1.8

pure

CY2017Q4

teva

Equity Value

EquityValue

19000000000

USD

CY2017Q4

teva

Market Capitalization

MarketCapitalization

21000000000

USD

CY2016

teva

Goodwill Impairment

GoodwillImpairment

-900000000

USD

CY2017

teva

Impairments Restructuring And Others2

ImpairmentsRestructuringAndOthers2

5100000000

USD

CY2017Q4

dei

Entity Public Float

EntityPublicFloat

1016877139

USD

CY2014Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

23355000000

USD

CY2016Q2

teva

Equivalent Share Units Approval For Grant

EquivalentShareUnitsApprovalForGrant

77000000

shares

CY2017

teva

Assumed Exercise Of Employees

AssumedExerciseOfEmployees

38000000

USD

CY2016

teva

Assumed Exercise Of Employees

AssumedExerciseOfEmployees

4000000

USD

CY2015

teva

Assumed Exercise Of Employees

AssumedExerciseOfEmployees

1000000

USD

CY2017Q4

teva

Venezuela Cash

VenezuelaCash

13000000

USD

CY2017Q4

teva

Venezuela Deconsolidation

VenezuelaDeconsolidation

396000000

USD

CY2017Q4

teva

Venezuela Deconsolidation Currency Adjustments

VenezuelaDeconsolidationCurrencyAdjustments

326000000

USD

CY2016Q4

us-gaap

Allowance For Doubtful Accounts Receivable

AllowanceForDoubtfulAccountsReceivable

191000000

USD

CY2017Q4

us-gaap

Allowance For Doubtful Accounts Receivable

AllowanceForDoubtfulAccountsReceivable

232000000

USD

CY2016Q4

teva

Asset Impairment Chargeslonglived Assets

AssetImpairmentChargeslonglivedAssets

589000000

USD

CY2015Q4

teva

Asset Impairment Chargeslonglived Assets

AssetImpairmentChargeslonglivedAssets

265000000

USD

CY2017Q4

teva

Unrecognized Compensation Cost Rsus

UnrecognizedCompensationCostRsus

142000000

USD

CY2017Q4

teva

Unrecognized Compensation Cost Options

UnrecognizedCompensationCostOptions

126000000

USD

CY2016Q4

teva

Foreign Currency Translation Attributable To Noncontrolling Interests

ForeignCurrencyTranslationAttributableToNoncontrollingInterests

60000000

USD

CY2015Q4

teva

Foreign Currency Translation Attributable To Noncontrolling Interests

ForeignCurrencyTranslationAttributableToNoncontrollingInterests

1000000

USD

CY2016Q4

us-gaap

Inventory Raw Materials

InventoryRawMaterials

1385000000

USD

CY2017Q4

us-gaap

Inventory Raw Materials

InventoryRawMaterials

1454000000

USD

CY2016Q4

us-gaap

Inventory Work In Process

InventoryWorkInProcess

538000000

USD

CY2017Q4

us-gaap

Inventory Work In Process

InventoryWorkInProcess

597000000

USD

CY2016Q4

us-gaap

Inventory Finished Goods

InventoryFinishedGoods

2832000000

USD

CY2017Q4

us-gaap

Inventory Finished Goods

InventoryFinishedGoods

2689000000

USD

CY2016Q4

us-gaap

Other Inventory In Transit

OtherInventoryInTransit

199000000

USD

CY2017Q4

us-gaap

Other Inventory In Transit

OtherInventoryInTransit

184000000

USD

CY2017Q4

teva

Cash Deposited With Financially Sound European Us And Israeli Banks And Financial Institutions

CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions

1100000000

USD

Name	View Source	Status
0001193125-18-039076-index-headers.html	Edgar Link	pending
0001193125-18-039076-index.html	Edgar Link	pending
0001193125-18-039076.txt	Edgar Link	pending
0001193125-18-039076-xbrl.zip	Edgar Link	pending
d529462d10k.htm	Edgar Link	pending
d529462dex1020.htm	Edgar Link	pending
d529462dex1021.htm	Edgar Link	pending
d529462dex1022.htm	Edgar Link	pending
d529462dex1023.htm	Edgar Link	pending
d529462dex1024.htm	Edgar Link	pending
d529462dex1025.htm	Edgar Link	pending
d529462dex1026.htm	Edgar Link	pending
d529462dex1027.htm	Edgar Link	pending
d529462dex1028.htm	Edgar Link	pending
d529462dex1029.htm	Edgar Link	pending
d529462dex1030.htm	Edgar Link	pending
d529462dex1031.htm	Edgar Link	pending
d529462dex1032.htm	Edgar Link	pending
d529462dex1033.htm	Edgar Link	pending
d529462dex1034.htm	Edgar Link	pending
d529462dex1035.htm	Edgar Link	pending
d529462dex1036.htm	Edgar Link	pending
d529462dex1037.htm	Edgar Link	pending
d529462dex1038.htm	Edgar Link	pending
d529462dex1039.htm	Edgar Link	pending
d529462dex1040.htm	Edgar Link	pending
d529462dex1041.htm	Edgar Link	pending
d529462dex1042.htm	Edgar Link	pending
d529462dex1043.htm	Edgar Link	pending
d529462dex1044.htm	Edgar Link	pending
d529462dex1045.htm	Edgar Link	pending
d529462dex1046.htm	Edgar Link	pending
d529462dex1049.htm	Edgar Link	pending
d529462dex1050.htm	Edgar Link	pending
d529462dex1051.htm	Edgar Link	pending
d529462dex1052.htm	Edgar Link	pending
d529462dex1053.htm	Edgar Link	pending
d529462dex1054.htm	Edgar Link	pending
d529462dex1055.htm	Edgar Link	pending
d529462dex1056.htm	Edgar Link	pending
d529462dex1057.htm	Edgar Link	pending
d529462dex1058.htm	Edgar Link	pending
d529462dex1059.htm	Edgar Link	pending
d529462dex106.htm	Edgar Link	pending
d529462dex1060.htm	Edgar Link	pending
d529462dex1061.htm	Edgar Link	pending
d529462dex1062.htm	Edgar Link	pending
d529462dex1063.htm	Edgar Link	pending
d529462dex1064.htm	Edgar Link	pending
d529462dex1065.htm	Edgar Link	pending
d529462dex1066.htm	Edgar Link	pending
d529462dex107.htm	Edgar Link	pending
d529462dex108.htm	Edgar Link	pending
d529462dex21.htm	Edgar Link	pending
d529462dex23.htm	Edgar Link	pending
d529462dex311.htm	Edgar Link	pending
d529462dex312.htm	Edgar Link	pending
d529462dex32.htm	Edgar Link	pending
d529462dex321.htm	Edgar Link	pending
d529462dex33.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g529462dsp034a.jpg	Edgar Link	pending
g529462dsp034b.jpg	Edgar Link	pending
g529462dsp035a.jpg	Edgar Link	pending
g529462dsp035b.jpg	Edgar Link	pending
g529462dsp24.jpg	Edgar Link	pending
g529462dsp40.jpg	Edgar Link	pending
g529462g0203031005585.jpg	Edgar Link	pending
g529462g0203034051057.jpg	Edgar Link	pending
g529462g0203074040805.jpg	Edgar Link	pending
g529462g0210010946646.jpg	Edgar Link	pending
g529462g0210010946755.jpg	Edgar Link	pending
g529462g0210011623738.jpg	Edgar Link	pending
g529462g39p45.jpg	Edgar Link	pending
g529462g53v58.jpg	Edgar Link	pending
g529462g55h77.jpg	Edgar Link	pending
g529462g98z51.jpg	Edgar Link	pending
g529462stamp12.jpg	Edgar Link	pending
g529462stamp24.jpg	Edgar Link	pending
g529462st_69.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
teva-20171231.xml	Edgar Link	completed
teva-20171231.xsd	Edgar Link	pending
teva-20171231_cal.xml	Edgar Link	unprocessable
teva-20171231_def.xml	Edgar Link	unprocessable
teva-20171231_lab.xml	Edgar Link	unprocessable
teva-20171231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TEVA
Stock $teva

2017 Q4 Form 10-K Financial Statement

#000119312518039076 Filed on February 12, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TEVA Stock $teva

2017 Q4 Form 10-K Financial Statement

#000119312518039076 Filed on February 12, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TEVA
Stock $teva